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SUMMARY 
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by 
recurrent genetic aberrations. The prognosis of childhood AML has significantly improved 
over the last two decades, nevertheless the 30% of cases still relapse
1–3
. Intensive efforts 
have been devoted to identify new genetic abnormalities and altered signalling pathways to 
better stratify patients in different risk classes in order to improve children survival treating 
them with a more specific therapy. However still half of the AML cases do not present a 
recurrent genetic aberration. Thus, during this PhD I focused on the identification of new 
molecular markers at diagnosis and the evaluation of known markers during the disease 
follow up. The prognostic value of these markers has been evaluated to improve patients 
stratification and whenever possible to suggest novel tailored treatments. The overall goal 
of this study was also to functionally dissect the leukemogenic mechanism of action of 
these new molecular markers, in order to find suitable candidate gene/pathway to be 
targeted in novel personalized therapies. 
Initially, a screening of new markers at diagnosis was performed in a large Italian 
cohort of pediatric AML defining the incidence of genetic abnormalities previously 
described as single case reports or as novel rearrangements identified by next-generation 
sequencing. The del(4)(q12)FIP1L1-PDGFRA, t(16;21)(p11;q22)FUS-ERG, 
t(8;16)(p11;p13)MOZ-CB, t(11;17)(q23;q12-21)MLL-AF17, t(4;11)(q35;q23)MLL-ARGB2, 
t(3;5)(q25;q34)NPM1-MLF1, MLLPTD, and t(11;17)(p15.5;p13)NUP98-PHF23 were 
finally classified to be rare events at diagnosis. An exception was the translocation 
t(5;11)(q35;p15.5)NUP98-NSD1 which reached an incidence of 4% and was found to 
occur together with FLT3-ITD mutation in more than 50% of cases. 
Then, the mutations of the oncogene c-KIT were taken into evaluation in a selected 
subset of CBF-rearranged patients since these abnormalities were previously reported to be 
frequent in adults with CFB-AML at diagnosis
4
. I defined a high frequency of c-KIT 
mutations for RUNX1-RUNX1T1 (25%) and for CBFB-MYH11 (18.5%) rearranged 
pediatric patients. Prognostic value of c-KIT mutations was determined only for the 
RUNX1-RUNX1T1 rearranged patients, suggesting that they could be further evaluated for 
a targeted therapy with tyrosine kinase inhibitors.  
Then, I take into consideration the evaluation of a molecular marker detected at 
diagnosis during therapy course, by evaluating the role of monitoring the minimal residual 
disease (MRD) by Real time RQ-PCR . In pediatric AML, post-treatment MRD monitoring 
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of biomarkers has been rarely used in the clinical management of patients:. molecular 
markers suitable for MRD detection still remains debated. I improved knowledge  for 
patients with AML1-ETO rearrangement and in FLT3-ITD mutation, revealing that MRD 
levels after induction chemotherapy were prognostically significant in identifying those 
with higher risk to relapse and die These new group of patients , within the same genetic 
subgroup, may benefit of novel risk stratification or pre-emptive therapy strategies 
supporting the t(8;21) and FLT3-ITD as reliable molecular markers for disease monitoring 
also during follow up.  
A large part of this PhD program was committed to dissect the biology of some 
recurrent aberrancies being their functional role investigation mandatory to develop new 
targeted therapies to improve children cure. I hypothesized that biology might explain the 
difference in therapy response highlighted in the MRD study performed on FLT3-
ITDpatientswhere half of them was found to reduce MRD levels less than 2 logs from 
diagnosis with a consequent high risk of relapse and death. By gene expression analyses , I 
showed that these patients had a different gene expression profile related to epigenetic 
control, most concerning methylation and acetylation of histones. These findings may 
suggest that the use of epigenetic drugs, combined with conventional strategies, could be a 
new therapeutic opportunity for a the FLT3-ITD patients showing high MRD levels after 
the end of first induction course. 
A second functional study was carried on the t(6;11)(q27;q23)MLL-AF6 
rearrangement. In the Italian AML cohort, 10% of AML patients are MLL-rearranged
5
 and 
among them the t(6;11) cases present the worst prognosis
5,6
. By in vitro studies, I found 
that wild type AF6 protein co-localized with RAS in the bone marrow of healthy donors, 
while AF6 was sequestered into the nucleus provoking RAS overactivation in 
t(6;11)(q27;q23) rearranged AML. The role of AF6 in RAS inhibition was confirmed by 
AF6 silencing or treatment with RAS antagonists, revealing the implication of RAS 
pathway in the aggressiveness of MLL-AF6 leukemia. This discovery confirmed the 
usefulness of Tipifarnib, a drug currently used in RASopathies
7
, in this AML subgroup, 
and opens for new targeted therapies to overcome their poor outcome. 
The third functional study was performed on a gene recently found implicated in 
several translocations being not rare (4.6%) in pediatric AML at diagnosis and with 
outcome severe prognosis, NUP98
8–10
. I deep inside the biology of all the NUP98 detected 
rearrangements, and identified a specific gene expression pattern as well as a typical 
outcome. Gene ontology revealed an enrichment in biological processes linked to the 
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nuclear organization and chromosome instability, confirmed also by in vitro studies on 
NUP98-NSD1 rearranged primary cells. Moreover, I reported CREB control in the 
transcription of NUP98 and consequently of its chimeras. Altogether, these findings open 
for further studies into the leukemogenic mechanism of NUP98-rearranged AML, and 
highlight CREB as a possible therapeutic target to decrease the oncogenic properties of 
NUP98-chimeras. 
Finally, during this PhD a variety of molecular lesions were identified permitting a 
more detailed diagnosis for pediatric AML. The prognostic significance of each marker 
was evaluated and included in the risk classes stratification of the new AIEOP LAM 2013 
protocol, conferring to genetics a strong role in guiding therapeutic strategies. Functional 
studies were able to characterize new candidate genes that can be  specific for a subgroups 
of AML patients with detrimental prognosis, to be further studied for their therapeutic role 
and when possible for a even more personalized therapy. All together, this work achieved 
results that are currently translated into clinical management, and will contribute to the 
improvement of the outcome of AML children. 
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SOMMARIO 
La leucemia acuta mieloide (LAM) è una malattia geneticamente 
eterogenea,caratterizzata da ricorrenti anomalie molecolari. Nonostante la prognosi dei 
pazienti pediatrici affetti da LAM sia notevolmente migliorata negli ultimi anni, il tasso di 
ripresa di malattia è di circa il 30% 
1–3
. Numerosi studi sono emersi per identificare nuove 
anomalie genetiche o vie di segnale deregolate nella LAM pediatrica al fine di migliorare 
la stratificazione dei pazienti nelle diverse classi di rischio, e di conseguenza poter adottare 
dei percorsi terapeutici specifici e più mirati. Ad oggi tuttavia, per circa il 50% dei casi non 
si trova alla diagnosi un marcatore molecolare noto in grado di garantire una corretta 
stratificazione del paziente. Per tale ragione il mio dottorato di ricerca ha avuto come 
primo scopo la ricerca e l’identificazione di nuovi marcatori molecolari alla diagnosi , e di 
studiarne il ruolo prognostico affinché si possa garantire una più corretta diagnosi a un più 
alto numero di pazienti, e si possa valutarne in caso un ruolo anche come marker di 
monitoraggi durante la terapia del paziente. Infine, allo scopo puramente diagnostico, è 
stato abbinato uno scopo di ricerca di base, cioè caratterizzare il processo neoplastico 
mediato da alcuni di questi marcatori molecolari, cercando di identificare dei geni malattia 
che possano servire essere dei candidati target terapeutici, utili a porre le basi per una 
gestione sempre più personalizzata e quindi efficace della terapia. 
Inizialmente ho effettuato una serie di screening molecolari con l’intento di valutare 
l'incidenza di alcune anomalie genetiche precedentemente conosciute solo tramite case 
report o identificate tramite sequenziamento massivo dell’RNA. In particolare, ho definito  
la del(4)(q12)FIP1L1-PDGFRA, la t(16;21)(p11;q22)FUS-ERG, la t(8;16)(p11;p13)MOZ-
CBP, la t(11;17)(q23;q12-21)MLL-AF17, t(4;11)(q35;q23)MLL-ARGB2, la 
t(3;5)(q25;q34)NPM1-MLF1, il MLLPTD, e la t(11;17)(p15.5;p13)NUP98-PHF23 come 
eventi mutazionali rari nella coorte pediatrica italiana arruolata nel protocollo LAM 2001-
02 (totale pazienti N=482). Al contrario, la t(5;11)(q35;p15.5)NUP98-NSD1 è stata 
riscontrata avvenire con una frequenza del 4%, e spesso in concomitanza alla mutazione 
FLT3-ITD (nel 50% dei casi). Tale traslocazione è stata inoltre valutata per il suo peso 
prognostico, rivelandosi un fattore prognostico negativo perché associato ad un elevato 
rischio di recidiva e morte. 
Poi, un altro screening ha riguardato la valutazione delle presenza di mutazioni a 
carico del gene c-KIT, in un gruppo di pazienti già con riarrangiamento del CBF. Le 
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mutazioni di questo recettore delle tirosin chinasi sono già state ampiamente descritte in 
numerosi studi soprattutto riguardanti pazienti adulti affetti da LAM
4
. I risultati 
confermano un’alta frequenza di mutazione di c-KIT anche nei pazienti pediatrici con  
t(8;21)RUNX1-RUNX1T1 (25%) e  con inv(16)CBFB-MYH11 ( 18.5%). Il valore 
prognostico negativo  è risultato significativo solo nel gruppo con RUNX1-RUNX1T1, per i 
quali, l’identificazione di queste mutazioni potrebbero supportare l’uso di eventuali terapie 
con inibitori delle tirosin chinasi per migliorare la loro cura. 
Oltre alla diagnosi, il marcatore molecolare può avere un ruolo fondamentale anche 
durante il corso della malattia. Mi sono occupata di mettere a punto lo studio della malattia 
residua minima (MRM) mediante PCR quantitativa per tre importanti marker ricorrenti 
nelle LAM pediatriche. Ad oggi, il monitoraggio della MRM nella LAM pediatrica è 
scarsamente utilizzato. Qui, si propone il monitoraggio della MRM  tramite la RQ-PCR 
dopo chemioterapia di induzione nei pazienti con t(8;21) e FLT3-ITD in grado di 
individuare i pazienti a più alto rischio di recidivare. Aver identificato la t(8;21) e FLT3-
ITD come buoni marcatori molecolari per il monitoraggi della MRM, consentirà ai clinici 
di poter valutare delle strategie alternative in quei pazienti che potrebbero beneficiare di 
terapie farmacologiche supplementari al fine di evitare la ripresa della malattia. 
Infine, molto tempo del mio dottorato è stato impegnato alla caratterizzazione 
biologica e funzionale di alcuni marcatori molecolari ricorrenti con il fine ultimo di 
identificare nuovi possibili target terapeutici per migliorare la cure e la sopravvivenza dei 
pazienti. In primis, ipotizzando che la diversa risposta terapeutica dei casi FLT3-ITD abbia 
origine da una diversità biologia, abbiamo effettuato delle analisi di espressione genica su 
questo gruppo di pazienti. Questo studio ha permesso di identificare un profilo di 
espressione genica caratteristico per i pazienti che riducendo meno la malattia dopo 
l’induzione vanno incontro a un più alto rischio di ricadere. I processi biologici arricchiti in 
questi pazienti sono risultati riguardare la metilazione e l’acetilazione degli istoni, 
suggerendo che eventuali agenti deacentilanti o demetilanti, in combinazione con la terapia 
convenzionale, possano migliorare la sopravvivenza libera da avventi avversi di questi 
pazienti. 
Un altro studio funzionale ha preso in esame la t(6;11)(q27;q23)MLL-AF6. Circa il 
10% della popolazione pediatrica italiana presenta uno dei riarrangiamenti a carico del 
gene MLL , tra questi la t(6;11) presenta la prognosi peggiore
5,6
. Attraverso studi in vitro, 
ho rivelato che la proteina AF6 endogena si localizza nel citoplasma insieme all’oncogene 
RAS in cellule di midollo osseo sano. Viceversa, nei pazienti con traslocazione t(6;11), 
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AF6 è stato riscontrato essere nel nucleo impedendo il fisiologico controllo di RAS nel 
citoplasma, comportandone un’iper-attivazione della via. Sia il silenziamento di AF6 sia il 
trattamento con inibitori di RAS hanno confermato il ruolo chiave del pathway di RAS nel 
sostenere l’aggressività di questa leucemia. Infine, lo studio ha comprovato il Tipifarnib, 
farmaco già in uso nelle RASopatie
7
, come nuovo farmaco utilizzabile nei pazienti 
pediatrici con t(6;11). 
Il terzo studio funzionale ha riguardato un gene molto nuovo nella LAM pediatrica, 
il gene NUP98. Le traslocazioni somatiche associate a questo gene
8–10
 si sono riscontrate 
non rare nella corte pediatrica LAM italiana (4.6%). Lo studio più funzionale ha poi 
chiarito che ciascuna di queste traslocazioni identificate una diversa biologia così come un 
diverso ruolo prognostico . Grazie all’analisi di espressione genica ho identificato 
l’instabilità genetica come il processo biologico maggiormente deregolato in questo gruppo 
di pazienti con NUP98-LAM. Tale processo è stato verificato in vitro grazie a colture 
cellulari primarie di pazienti NUP98-NSD1 riarrangiati. Inoltre, ho dimostrato che il fattore 
di trascrizione CREB controlla la trascrizione del gene NUP98, cosi come di tutte le 
oncoproteine che si riscontrano nelle LAM mantenere l’N terminale dello stesso. Questi 
risultati identificano il ruolo funzionale della chimera NUP98-NSD1, e candidano  CREB a 
possibile bersaglio terapeutico per combattere l’espressione della chimera e quindi la 
progressione della malattia . 
In conclusione, durante i tre anni di dottorato di ricerca ho caratterizzato una serie 
di marcatori molecolari che hanno permesso una migliore e più dettagliata stratificazione 
dei pazienti alla diagnosi. Dato il valore prognostico dei vari marcatori, essi sono stati 
inclusi nel nuovo protocollo terapeutico LAM 2013, che conferisce alla genetica 
molecolare un ruolo determinante nel guidare la terapia. Infine gli studi funzionali hanno 
finora portato all‘identificazione di nuovi target specifici in vari sottogruppi di LAM a 
prognosi infausta. Studi futuri sono in corso per  valutare questi biomarcatori come target 
terapeutici da utilizzare per incrementare le possibilità di curare i bambini affetti da LAM . 
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ACUTE MYELOID LEUKEMIA 
Hematopoiesis is a tightly controlled process in which transcription factors and chromatin 
remodeling genes finally orchestrated the gene expression that defines the phenotype of a 
blood cell. The hematopoietic hierarchy begins from the pluripotent hematopoietic stem 
cell (HSC) which, thanks to its hematopoietic potential, gives rise to both the 
hematopoietic lineages, lymphoid and myeloid. Ineffective hematopoiesis, resulting in 
homeostatic imbalance in the production of blood cells, led to a series of hematological 
disorders. Leukemia is the most common hematological malignancy occurring during 
childhood. Its origin depends on the progenitor cell that is affected for differentiation and 
proliferation capabilities, that subdivides leukemias in  lymphoblastic leukemia , whena 
lymphoid progenitor cell is mutated, or myeloid leukemia, when the precursor is from the 
myeloid lineage
1
. 
Acute Myeloid Leukemia (AML) is relatively rare (15%–20% of overall leukemia in the 
childhood) characterized by the uncontrolled proliferation, increased survival and impaired 
differentiation of hematopoiesis as result of distinct but cooperative mutations acquisition. 
These neoplastic cells, called blast cells, accumulate in the bone marrow and others organs 
originating the onset of acute leukemia. To be called acute, these abnormal immature 
leukemic cells, known as blasts, must be present in bone marrow for a percentage greater 
than >20%
1,2
. The neoplastic myeloblasts can be arrested in a variety of differentiation 
stages, supporting the loss of the normal hematopoietic function due to alteration of self-
renewal, proliferation, and differentiation.  
 
Figure 1. Cellular origin of Acute Myeloid Leukemia shows the differentiation of normal lymphoid and 
myeloid lineage from hematopoietic stem cells. Yellow arrow points at the abnormal undifferentiated 
leukemic blast cells (Modified from How stem cells work by Stephanie Watson). 
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The new era of genomic sequencing and high throughput technology has recently refined 
the current hypothesis of the AML development. In the first step of the leukemogenesis, a 
driver mutation occurs within the context of a HSC
3,4
. This alteration confers a 
proliferative advantage to the cell allowing the clonal expansion, carrying along all the 
background mutations within its genome (passengers). An additional driver mutation 
occurs within a committed cell forming the expanding clone which becomes the leukemic 
“founding” clone detected at the diagnosis. Thus, these cells are supported to contain only 
a few drivers but many passengers mutations
5–7
. By next generation sequencing studies 
novel mutations occur at the founding clone that can sustain a relapsing clone able to 
survive at the chemotherapy
6,8
. Therefore, the AML model is becoming increasingly 
sophisticated and debated, particularly in pediatric field. Intense efforts have been devoted 
to identify the genetic mutations require for the malignant transformation. Recent reports 
highlight that Class I (that confer a proliferative and survival advantage) and Class II 
(impair differentiation and apoptosis) mutations are only one part of a more complex 
picture
9
. New mutations have been identify in AML genome that might have a pivotal role 
in the leukemogenic process and constitute new classes, such as mutations at genes 
involved in epigenetic modifications (Class III), cell adhesion (Class IV) and DNA repair 
(Class V)
10–12
 (figure 2). 
In this new scenario AML constitutes an exceptional biological model of cooperative 
genetic and epigenetic alterations that initiate the myeloid transformation, a clonal disease 
and its progression. 
 
Figure 2. Molecular pathogenesis of AML. Five class of mutations involved in the AML development (from 
Hematology Education 2012, C.T Hien) 
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A CLINICAL POINT OF VIEW  
AML has an extremely heterogeneous nature recognized as differences in cell 
morphology, immunophenotype, cytogenetics and molecular genetics. This variability is 
due to the diversity of myeloid precursor susceptible to malignant transformation, as well 
as for the multiplicity of the events that orchestrate the genome control. The vast majority 
of AML cases can be classified according to specific clinical-biological features and 
genetic abnormalities able to identify distinct subtypes of leukemia
13
. 
Molecular genetics of AML 
Childhood acute leukemia has long been the best characterized malignancies from 
the genetic point of view. Despite the continuous identification of molecular lesions that 
guide prognosis and patients clinical management, AML remains highly heterogeneous 
disease within the 50% of patients that are actually without a known molecular marker. 
Thus, the identification of novel prognostic factors AML remains one of the main needs for 
the improvement of AML knowledge and patients survival. Next-generation sequencing of 
AML has recently shown hundreds of novel genetic lesions within this disease, 
representing an important advance in order to dissect the leukemogenic process and 
prognosis and to stimulate the development of targeted therapy. Although, results revealed 
that the most represented mutations still remain those genomic mutations previously 
known to occur at RUNX1, MLL, FLT3, CEBPA, NPM1 and c-KIT genes 
14,15
. Nevertheless 
the huge improvements of novel mutations were no recurrent, nor in vitro studies are 
present that can define them as prognostic factor since now. For this, we consider that the 
80% of the AML children have disease-associated genomic structural alterations, 65% of 
those without cytogenetic abnormalities (normal karyotype) have one of known mutations; 
thus more than 90% of pediatric AML cases are identified to have at least one known 
genomic alteration (figure 3)
14
, and that each individual case of AML harbor a huge 
number of mutations at specific genes whose role remain elusive
16,17
.  
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Figure 3. Estimated frequency of specific genotypes in childhood acute myeloid leukemia. Panel to the left 
demonstrates the most common karyotypic alterations. Eighty percent of all children have disease-associated 
genomic structural alterations. Mutation profile in those without cytogenetic abnormalities (normal 
karyotype) is shown in the right panel. Seventy-six percent of those in the normal karyotype population have 
one of the known mutations; thus, more than 95% of all children with AML have at least one known genomic 
abnormality
14
. 
Prognostic Factor and Risk Stratification in Pediatric AML 
This genetic characterization is still an open challenge for pediatric AML for both 
reasons to take new insight into the pathogenesis of AML, but also to improve prognostic 
risk assessment and subsequently clinical therapeutic strategies. In the past, many clinical 
biomarkers have been replaced by cytogenetic and molecular features defining a risk-
adopted therapy for pediatric AML. The core-binding factor (CBF) translocations, such as 
inv(16)(p13.1;q22)CBFB-MYH11, t(16;16)(p13.1;q22)CBFB-MYH11 and 
t(8;21)(q22;q22)RUNX1-RUNX1T1 are classified as standard risk (SR) for their favorable 
impact by several international groups
15
, all of whom reported overall survival (OS) rates 
of over 85%. Mutations at the NPM1 and CEBPA genes are less common in childhood 
AML than in adults, they appear to be associated with a similarly favorable outcome
14,15
. 
Among the molecular markers of high-risk (HR) of relapse there are the FLT3 mutations, a 
family that includes internal tandem duplication (FLT3-ITD) and point mutations in the 
kinase domain (FLT3-KD). The FLT3-ITDs occurs in approximately 10% to 20% of 
pediatric AML and may be gained or lost at the time of relapse
18,19
. Although these 
mutations, patients affected with deletion of chromosome 5, 7 (5-,7-), del(5q) share a poor 
prognosis. One important AML subtype is made up of patients carrying the MLL-
rearrangements. These AML are the most heterogeneous among all genetic subtype of this 
disease, and the prognostic impact of MLL rearrangement is mostly poor
20
. The MLL gene 
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located at 11q23 is notoriously promiscuous and has more than 120 translocation partners 
described; AML with t(1;11)(q21;q23) is rare but has a good outcome, whereas disease 
with t(6;11)(q27;q23), t(10;11)(p12;q23), or t(10;11)(p11.2;q23) had dismal outcome
20,21
. 
Repetitive rearrangements that involved NUP98 have been identified in recent works
22–24
. 
The cryptic translocations NUP98-NSD1 has been recently described in AML pediatric 
patients with a frequency of 4.4% and it occurred frequently with FLT3-ITD mutation, 
mediating a poor outcome
22
. Mutations in Wilms tumor 1(WT1) gene have yielded variable 
outcome reports from different countries
25,26
. Recently novel recurrent gene mutations in 
adults AML (at DNMT3a, IDH1 and IDH2) have been identified with low frequency in 
pediatric cohorts
27,28
 
Treatment and Outcome 
Conventional AML therapy is based on intensive use of cytarabine and/or 
anthracycline, and etoposide that is frequently used in pediatric induction regiments. The 
clinical outcome of pediatric AML has significantly improved over the past few decades, 
with current 8 years old EFS and OS of 55% and 68%, respectively, achieved in the 
multicenter AIEOP AML 2002/01 protocol
29
. The survival rates are similar to those 
obtained by several cooperative groups (table 1)
15
. This improvement was largely due to a 
stratification of patients in risk classes with a consequent risk-directed therapy, to the 
optimization in induction and post remission treatment strategy (high-dose of cytarabine). 
The SR patients (carrying CBF rearrangements) achieved morphological complete 
remission after the first induction course with idarubicin, cytarabine and etopiside (ICE). 
Instead for children who require an intensive therapy, the chemotherapeutic regimens 
consist of 4–5 cycles of intensive chemotherapy, typically including cytarabine combined 
with an anthracycline. In younger adult patients, results from previous trials suggested that 
there is a benefit for outcome using high-dose cytarabine in induction, but a similar effect 
in pediatric AML patients could not be confirmed
29–31
. Beside chemotherapy, the added 
value of hematopoietic stem cell transplantation (SCT) in newly-diagnosed pediatric AML 
is becoming stronger. SCT in first CR has been used only for the HR group in the AIEOP 
AML 2002/01 protocol, and in a more selected subset of high risk cases for others 
international groups
32
. The Italian studies reveled that the use of auto- or allo-HSCT in HR 
patients results in lower incidence of leukemia recurrence, with an acceptable treatment-
related mortality
29
. 
Despite intensive treatment, around 30% of the pediatric patients relapse, which confers 
high morbidity and mortality
14,15
. Notably the outcome in the Italian cohort of SR patients 
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was found inferior to that reported in other groups. In fact a larger than expected proportion 
of patients carrying either t(8;21) or inv(16) relapses
33
. To date, there is no explanation for 
this result. Furthermore, the high frequency of treatment-related deaths (5%–10%), both in 
treatment protocols for newly-diagnosed, as well as for relapsed disease, the acute toxicity 
(cardiotoxicity), and the secondary malignancy highlight that an additional intensification 
of chemotherapy seems no longer feasible
2,34
. Therefore, further knowledge on the 
molecular and genetic background is urgent in order to detect novel leukemia and patient-
specific treatment targets which are less toxic and more effective. 
Table 1. Summary of the Major International Cooperative Groups
15 
Minimal Residual Disease 
Disease relapse still remains the most important cause of treatment failure in AML. 
Molecular monitoring of response to treatment by minimal residual disease (MRD) 
provides important information to tailor treatment in acute lymphoblastic leukemia
35
. On 
the contrary, on the AML patients MRD has rarely been used in the prospective risk 
stratification. 
The lack of evidence about MRD thresholds, the choice of the most informative MRD time 
points, and the lack of standardized MRD assays have implied that MRD has never been 
considered as a prognostic tool directed therapy in the pediatric setting. MRD has variable 
prognostic power depending on the time of assessment. A rapid evaluation of tumor 
clearance after induction therapy may be critical, and some investigators have found that 
post-consolidation MRD levels carry superior prognostic power
36
. Early MRD detection 
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provided important information not only improving the outcome but also monitoring the 
excessive therapy toxicities and avoid the patients exposition to unnecessary additional 
treatment.  
The prognostic value of the response measured by flow cytometry after induction and 
consolidation therapy has been shown to provide independent prognostic information in 
pediatric AML
37
 but few data are available to support the clinical relevance of the 
molecular MRD in the risk stratification. In the pediatric AML the detection of MRD by a 
flowcytometric analysis has been associated with adverse prognosis, and MRD evaluation 
was included in the  international clinical trials
36
. Up to now, also the new AIEOP-LAM 
2013/01 protocol would consider MRD levels assessed during follow up by flow cytometry 
technique. The retrospective study performed on 160 patients enrolled at AIEOP AML 
2002/01 protocol revealed that MRD at the end of the first induction provides important 
prognostic information that will be used to improve stratification and to guide the therapy 
of childhood
38
. Intensive efforts are currently been devoted to the development of 
molecular methods able to evaluate residual AML burden by fusion transcript detection, 
that go beyond the sensibility of the flow cytometry (0,01%), and can improve 
flowcytometric evaluation for the cases where bone marrow regeneration can misinterpret 
blasts presence.  
High throughput approaches to Pediatric AML 
In order to provide more insight into the heterogeneity and biology of AML, high 
throughput technology has been used to allow an unbiased view on small genomic 
abnormalities, deregulated pathways and drug response. Array-based comparative genomic 
hybridization (array-CGH) and single-nucleotide polymorphism (SNP) arrays identified 
several regions with loss of heterozygosity and recurrent copy number variations (CNVs), 
although with low frequency in AML
39
. Gene expression profiling using microarray-based 
methodologies has provided new insights into the biology of a variety of hematopoietic 
malignancies. The gene signatures have proven to be robust discriminators of the specific 
subtypes of leukemia, showing diagnostic accuracies that, in many cases, exceed those 
achieved using routine diagnostic approaches
40
. The expression signature for each of the 
different leukemia subtypes could provide insights into the underlying pathobiology. 
Furthermore the differentially expressed genes could be evaluated as specific targets to be 
further investigated
40–42
. Gene expression profiles cannot be considered in cancer biology 
without the recent predominant discovered role played by the non coding RNAs (ncRNAs). 
ncRNAs have emerged as crucial regulators of gene expression, epigenetics and cell fate 
18 
 
decisions
43,44
. ncRNAs include highly abundant and functionally important RNAs, such as 
ribosomal RNAs (rRNAs), transfer (tRNAs), small nuclear RNAs (snRNAs), and small 
nucleolar RNAs (snoRNAs), and two more important , the microRNAs (miRNAs) and long 
ncRNAs (lncRNAs), which have been  already involved  in the regulation of gene 
expression of cancers. miRNAs are the most studied regulative non-coding RNAs. 
Differences in miRNAs expression levels have been associated with specific cytogenetic 
and molecular subsets of AML (miRNAs signature). Changes in the expression of several 
miRNAs altered in AML have been shown to have functional relevance in leukemogenesis, 
by acting as oncogenes as well as tumor suppressors
45,46
. If the impact of microRNAs on 
haematological malignancies has been well described, very little is known about the 
precise function of the lncRNAs (RNA molecules longer than 200 nucleotides)
47
. The 
lncRNAs linked to the HOXA cluster called HOTAIRM1, HOTAIR and HOTTIP have been 
described on leukemia. In particular, they were found to strictly control the expression of 
different HOXA genes, which are important transcriptional regulators in normal and 
malignant hematopoiesis
48
. Another class of ncRNAs, the snoRNAs, was found 
misregulated in leukemia but their role nor targets are still unclear, even if they seem to be 
activators of translation and RNA splicing
44,49,50
. Recently, it has been identified that 
snoRNAs expression can delineate a specific profile in multiple myeloma and multiple 
myeloma
51,52
. The ncRNAs aberrant regulation adds a further level of complexity to the 
heterogeneity of AML, and may be a new biological source  to discover new biomarkers 
and molecular pathways associated to leukemogenesis. Actually, the gene expression
53,54
 
role in dissecting AML cannot be evaluated without considering the role of epigenetic, 
including the DNA methylation and histone modifications. Several studies have already 
disclose the ability of methylation profiles to distinguish cytogenetic subtypes of adult 
AML and to predict the clinical outcome
9,55
. A central role of epigenetic in AML process 
has been linked to the presence of mutations and translocations at genes involved in these 
processes, as TET2, DNMT3A, IDH1, IDH2, EZH2
56,57
but these aberrancies occur with a 
very low frequency in AML childhood
27,28
. Further studies are needed to understand 
epigenetic mechanisms to dissect patients eligible for new treatment opportunities with 
demethylating agents or histone modification inhibitors currently adopted as important and 
strategic new drugs in several hematologic diseases
58,59
. 
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The clinical outcome of pediatric AML has improved significantly over the past 
few decades but still the 30% of the patients relapse, which confers high morbidity and 
mortality. Intense efforts have been devoted to molecular classification, however the 50% 
of children with myeloid leukemia still do not present a known recurrent molecular marker. 
The aim of this study is to disclose new chromosomal rearrangements, as well as gene 
mutations and dissect their role of new biomarkers in pediatric AML group, to be used to 
refine prognostic stratification and suggest differentially tailored treatment, based on 
integrated genetic profiles. Furthermore, their use as suitable molecular markers for the 
molecular monitoring of minimal residual disease (MRD) during follow-up would be 
studied to define  treatment response, predict relapse and direct therapy decision. Secondly, 
these new markers would be biologically and functionally studied to better dissect the 
pathology of AML. This is translation research, which would provide comprehensive 
genetic analyses to the clinical setting to enable genotype-specific therapies for a 
personalized treatment of patients with AML. 
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LETTER TO THE EDITOR 
Acute myeloid leukemia (AML) is a heterogeneous disease with known specific 
recurrent genetic aberrations. The continuous and increasing identification of new genetic 
lesions has permitted to identify new subgroups of patients with different prognosis
1
. In the 
present work, we evaluated the incidence of rare genetic abnormalities in pediatric AML 
such as del(4)(q12)FIP1L1-PDGFRA, t(16;21)(p11;q22)FUS/ERG, 
t(8;16)(p11;p13)MOZ/CBP,  t(11;17)(q23;q12-21)MLL/AF17, 
t(4;11)(q35;q23)MLL/ArgB2, t(5;11)(q35;p15.5)NUP98/NSD1, 
t(3;5)(q25;q34)NPM1/MLF1, and MLLPTD in 306 children with newly diagnosed de novo 
AML other than acute promyelocytic leukemia enrolled in AIEOP centers from 2000 to 
2009,
2 
all negative for known recurrent genetic abnormalities involving MLL, CBF-beta 
and FLT3 genes (77 males and 77 females, median age at diagnosis 7.2 years, range 17 
days–17 years). RNA was extracted from fresh bone marrow at diagnosis, and multiplex 
RT-PCR was employed. Sequencing by Sanger method was applied to all positive cases to 
characterize fusion breakpoints. 
We identified one patient each positive for t(16;21)(p11;q22)FUS-ERG, 
t(11;17)(q23;q12-21)MLL-AF17, and t(4;11)(q35;q23)MLL-ArgB2, respectively, this 
suggesting that these rearrangements are extremely rare in pediatric AML. 2/306 patients 
had del(4)(q12)FIP1L1-PDGFRA, and 4/306 had t(8;16)(p11;p13)MOZ-CBP. 
Interestingly, 6/306 (2%) patients had t(3;5)(q25;q34)NPM1-MLF1, 6/306 (2%) had 
MLLPTD, and 6/306 (2%) were found to carry t(5;11)(q35;p15.5)NUP98-NSD1. In our 
pediatric cohort, the incidence of this last aberration is lower than that previously reported 
by Hollink et al.
3
 Subsequently, since a strong association of t(5;11) fusion with FLT3-ITD 
has been described (91%),
3 
 we extended the screening to 42 children with de novo AML 
harboring the FLT3-ITD mutation, enrolled in the AIEOP-LAM 2002 protocol. We found 
that 6/42 (14%) had the NUP98-NSD1 fusion. So, six out of 12 NUP98/NSD1-positive 
patients (50%) were FLT3-ITD positive, showing a lower association in our pediatric 
cohort for these two aberrancies than that reported by Hollink et al.
3
 Then, we looked at the 
event-free survival (EFS) of patients with t(5;11)NUP98-NDS1 (n=12) and found that it 
was worse, as compared with patients negative for known molecular lesions and enrolled 
into the LAM 2002-AIEOP protocol (30.1% vs. 57.1% at 3 years, p<0.05).
4
 Furthermore, 
we did not find any difference in either clinical or biological features between patients with 
isolated t(5;11) and those with t(5;11)+FLT3-ITD (Figure 1). The 8-year EFS of FLT3-
ITD+ children who did or did not carry t(5,11) was 33.3% and 42.7% (p= 0.2), 
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respectively. This finding suggested that NUP98-NSD1 fusion protein identifies a 
previously unrecognized subgroup of FLT3-ITD patients with an even worse prognosis.  
 
 
Figure 1. A) Probability of event-free survival (EFS) in children with NUP98-NSD1 rearrangement in AML. 
EFS for patients NUP98-NSD1-positive (n = 12, 30.1%) vs. negative patients (n = 142, 57.1%). B) NUP98-
NSD1 rearranged patient’s main features.   
To test whether MLLPTD might also play a role in the occurrence of childhood AML 
relapse, we analyzed samples from 40 AML at relapse, never finding this abnormality. By 
contrast, 4 patients harbored at relapse the same MLLPTD found at diagnosis, suggesting 
the stability of this mutation.  
In summary, we confirm that t(5,11) is not exceptional in pediatric AML, being 
frequently associated with FLT3-ITD, and identifying patients at high risk of treatment 
failure. We also suggest a negative role of this translocation in FLT3-ITD positive patients 
to be further considered in the risk stratification of patients. The putative role of the 
remaining rare abnormalities 
5,6
 in AML remains to be confirmed in prospective studies 
with larger cohort of patients.  
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LETTER TO THE EDITOR 
ABSTRACT 
The genomic landscape of children with acute myeloid leukemia (AML) who do 
not carry any cytogenetic abnormality (CN-AML) is particularly heterogeneous and 
challenging, being characterized by different clinical outcomes. To provide new genetic 
insights into this AML subset, we analyzed through RNA-seq 13 pediatric CN-AML cases, 
corroborating our findings in an independent cohort of 168 AML patients enrolled in the 
AIEOP AML 2002/01 study. We identified a chimeric transcript involving NUP98 and 
PHF23, resulting from a cryptic t(11;17)(p15;p13) translocation, demonstrating, for the 
first time, that NUP98-PHF23 is a novel recurrent (2.6 %) abnormality in pediatric CN-
AML. 
 
FINDINGS  
Childhood acute myeloid leukemia (AML) is a heterogeneous disease with current 
survival rates of approximately 60–70 %. Cytogenetics, recurrent molecular abnormalities, 
and early response to treatment are the main factors influencing outcome
1
. However, 
around 20 % of pediatric AML do not carry any known cytogenetic abnormality 
(cytogenetically normal-AML or CN-AML). In order to shed light on this subgroup we 
performed whole-transcriptome sequencing (WTS) in 13 pediatric CN-AML cases, 
corroborating relevant findings in an independent cohort of 168 cases. Sequencing was 
performed on a HiScanSQ sequencer (Illumina), and bioinformatic analysis was performed 
as previously described
2
. 
In 2 (CN-AML_54, CN-AML_66) out of 13 cases analyzed, we identified a 
chimeric transcript involving nucleoporin 98 kDa (NUP98) and PHD finger protein 23 
(PHF23) genes, resulting from a cryptic translocation t(11;17)(p15;p13) (Fig. 1a and Table 
1). In both cases, we identified an in-frame fusion between NUP98 exon 13 and PHF23 
exon 4 (Fig. 1b). To date, the cryptic translocation t(11;17)(p15;p13) has been described 
only once in an adult AML patient 
3
, but never in a pediatric AML cohort. Different from 
what was previously reported by Reader and colleagues 
3
, in this study the recurrent 
breakpoint in PHF23 was always identified at the beginning of exon 4 and not within it 
(Fig. 1a and b). 
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Table 1. Clinical features of pediatric CN-AML patients harboring the NUP98-PHF23 fusion gene. *, 
patients identified by RNA-seq; †, dead patient; AUTO, autologous; CR, complete remission; HSCT, 
hematopoietic stem cell transplantation; MUD, matched unrelated donor; WBC, white blood cells 
 To assess the incidence of NUP98-PHF23 fusion in pediatric CN-AML, we 
examined through RT-PCR analysis and Sanger sequencing a validation cohort of 168 
AML children enrolled in the AIEOP AML 2002/01 study
4
; one-hundred thirty-nine 
patients (76 males and 63 females, median age at diagnosis 7.7 years, range 17 days to 17.9 
years) were negative for known recurrent genetic abnormalities involving MLL, CBFB, and 
FLT3, while the remaining 29 patients (15 males and 14 females, median age at diagnosis 
11.8 years, range 3 to 17.4 years) harbored internal tandem duplication of FLT3 (FLT3-
ITD), this latter abnormality being chosen because we previously reported a strong 
association between NUP98-NSD1 rearrangement and FLT3-ITD
5
. With the exception of 
FAB M3 (acute promyelocytic leukemia), all the FAB types were represented in the 
validation cohort. RNA was extracted from fresh bone marrow at diagnosis, and multiplex 
RT-PCR was used. Sequencing by Sanger method was applied to all casespositive by PCR 
to NUP98-PHF23 fusion gene. Overall, 2 out of 139 CN-AML cases were found to harbor 
NUP98-PHF23 (Table 1). NUP98-PHF23 was not found in any patient harboring FLT3-
ITD. Fluorescence in-situ hybridization confirmed the cryptic chromosomal translocation 
t(7;11)(p15;p13) leading to the fusion between NUP98 and PHF23 in all cases (Fig. 1c).  
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Figure 1. Identification of NUP98-PHF23 in pediatric CN-AML. A. Schematic representation of NUP98-
PHF23 fusion identified by RNA-seq in pediatric CN-AML. Fusion occurs between exon 13 of NUP98 and 
exon 4 of PHF23. B. Electropherogram from Sanger sequencing of the region surrounding the breakpoint 
confirmed the in-frame fusion. A black arrow indicates the fusion breakpoint, predicted sequence of the 
fusion protein is shown. C. FISH analysis was performed on metaphases and interphase cells using three Blue 
FISH probes (BlueGnome Ltd., Cambridge), according to the manufacturer’s instructions. BAC clones RP11-
120E20 and RP11-348A20 (red) were used to probe the NUP98 gene on chromosome 11, while the BAC 
clone RP11-542C16 (green) was used to target the PHF23 gene on chromosome 17. Normal metaphases 
(upper left) and interphase nuclei (upper right) showed two red signals representing normal copies of NUP98 
and two green signals representing normal copies of PHF23. Abnormal metaphases (lower left) and 
interphase cells (lower right) containing the NUP98-PHF23 fusion gene showed one red (NUP98), one green 
(PHF23) and one yellow fusion signal, which represents the juxtaposition of the translocated portions of the 
two genes. 
 
So far, many NUP98-rearrangements have been found to be associated with both de 
novo and therapy-related AML but also with T-cell acute lymphoblastic leukemia with 
over 28 different partner genes 
6
. Recently, the fusion NUP98-JARID1A has been described 
to be a recurrent event in pediatric acute megakaryoblastic leukemia (11 %), with a distinct 
HOX gene-expression pattern 
7
. Conversely, chromosomal rearrangements and/or 
mutations of PHF23 have never been previously described in children with AML. Located 
on the reverse strand of 17p13.1, PHF23 encodes for a protein containing a plant 
homeodomain (PHD) finger 
8
 involved in chromatin remodeling
3
. Expression of NUP98-
PHF23 has been demonstrated to impair the differentiation of myeloid progenitor cells and 
promote leukemia development in vitro and in vivo 
8–10
. Cells expressing NUP98-PHF23 
are sensitive to disulfiram, an FDA-approved drug, demonstrating the feasibility of 
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targeting this oncoprotein 
9
. In summary, we identified, for the first time in childhood 
AML, a NUP98-PHF23 fusion, demonstrating that this genomic aberrancy is not 
exceptional (tentative frequency of 2.6 %) in pediatric CN-AML. These findings enforce 
the role of epigenetic regulators in pediatric AML and suggest novel therapeutic targets for 
this disease. 
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LETTER TO THE EDITOR 
The proto-oncogene c-KIT, which encodes a receptor for stem cell factor (SCF), 
belongs to the type-III receptor of the tyrosine kinase subfamily and is characterized by 
five extracellular immunoglobulin-like domains, a single transmembrane helix (TM), a 
cytoplasmic juxtamembrane domain (JMD), and a kinase domain. Abnormal activation of 
c-KIT/SCF growth signal has been frequently documented to occur in cancers, including 
hematological malignancies, and has been frequently associated with poor prognosis in 
adults with acute myeloid leukemia (AML) harboring aberrancies at core binding factor 
genes (CBF)
1-3
. c-KIT mutations have been reported in pediatric CBF-rearranged AML at 
frequencies ranging from 15 to 54.5%; however, their prognostic significance is still 
debated 
4-7
. Mutations of c-KIT occur in the extracellular portion of the receptor implicated 
in dimerization within exon 8, in the TM-JMD domain within exon 11, and in the 
activation loop of the tyrosine kinase domain within exon 17, this mediating the 
constitutive activation of the receptor. The AIEOP AML2002/01 protocol allocated 
patients with CBF rearrangements in the standard-risk (SR) group, and, although all these 
patients reached complete remission after the first 2 induction courses, they showed a 
higher than expected cumulative incidence of relapse (24%)
8
. The identification of new 
independent prognostic factors and therapeutic targets is desirable to optimize the outcome 
of this subgroup of childhood AML. In particular, our interest focused on determining 
whether the presence of c-KIT mutation could have a prognostic impact and could allow 
refining the risk stratification for this subgroup of AML patients.  
We retrospectively analyzed the bone marrow at diagnosis of 88 children with 
CBF-AML enrolled in the SR group of the AIEOP AML2002/01 protocol. Sixty-one 
patients carried t(8;21)RUNX1-RUNX1T1, 26 inv(16)(p13;q22)CBFB-MYH11 and 1 
t(16;16)(p13;q22)CBFB-MYH11. Screening for mutations of c-KIT was performed on 
cDNA by PCR amplification followed by Sanger sequencing of exons 8 and 17, or analysis 
by the Genescan and Genemapper software (Applied Biosystems Inc) for exon 11. The 
primers used are listed in Table 1S. Denaturing, annealing and extension step were 
performed at 95°C for 30 seconds, 60°C for 30 seconds, 72°C for 30 seconds, respectively, 
for a total of 40 cycles on a thermocycler. PCR products were resolved on a 2% agarose 
gel. After visual confirmation of amplification, 4 µl of PCR products of exon 8 or 17 were 
purified with a mixture of 0.5 µl Exonuclease I and 1 µl of FastAP™ Thermosensitive 
Alkaline Phosphatase (Thermo Scientific) and analyzed by bidirectional sequencing on an 
ABI310 sequencer, using the BigDye terminator kit v3.1 (Applied Biosystems Inc).  
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The prognostic impact of c-KIT mutation was assessed analyzing overall and event-
free survival (OS, EFS) probabilities; the Log-Rank (Mantel-Cox) test was employed to 
detect differences between subgroups. The screening showed that 5/61 (8%) t(8;21) 
patients were positive for a point mutation at either codon D816 or N822, affecting the 
activation loop of the kinase; 1/61 for internal tandem duplication at exon 11, and 9/61 
(15%) for small deletions and/or insertions of variable size in the extracellular portion of 
the receptor (exon 8). Overall, we found that, among the 61 patients harboring the RUNX1-
RUNX1T1 translocation, 15 were mutated for c-KIT (25%). In the cohort of CBFB-
MYH11-rearranged patients, we documented a lower incidence of c-KIT mutations, being 
found in 5 patients out of the 27 analyzed (18.5%) (Table 1). In inv(16)/t(16;16)-
rearranged patients, the mutations were found predominantly in exon 8 (4/5), with just one 
patient harboring D816V; none had internal tandem duplication. 
 
Table 1. Clinical characteristic of c-KIT mutated CBF patients. WBC = white blood cell; RFS = relapse free 
survival; OS = overall survival, ITD = internal tandem duplication, nt = nucleotides 
Interestingly, RUNX1-RUNX1T1-rearranged patients and c-KIT-mutated patients 
had a significantly worse 4-year OS (51.9%; SE 14.3%) and EFS (51.8%; SE = 14.3%) 
than patients with isolated t(8;21) (OS = 89.6%, SE = 6.9%, p = 0.0002; Figure 1A; EFS = 
78.3%, SE = 6.4%; p = 0.0176; Figure 1B), suggesting that c-KIT mutations might 
contribute to the inferior outcome reported for this subgroup of AML, which has been 
considered at good prognosis by different collaborative international groups. We highlight 
that RUNX1-RUNX1T1-rearranged patients without c-KIT mutations reached the expected 
survival (90%) for this SR group. The number of c-KIT-mutated, CBFB-MYH11-
rearranged patients was too small for permitting to find, if any, statistical differences in 
42 
 
terms of outcome in comparison to patients who did not carry the c-KIT mutation. 
Noteworthy, there was no statistically significant difference between c-KIT-mutated and 
not mutated CBF-rearranged patients in terms of the main clinical features (see also Table 
2S). 
 
Figure 1. Overall (A) and event free survival (B) probabilities of patients with and without c-KIT mutations 
harboring RUNX1-RUNTX1 rearrangement. 
The prognostic significance of c-KIT mutation in other pediatric CBF-AML cohorts 
has been reported to be different in previously published studies. Goemans et al (5) 
identified c-KIT aberrancies in 10/27 children (37%), with a higher incidence of mutation 
in inv(16) compared to t(8;21) (54.5% vs 31.3%). Shih et al.
6
 detected abnormalities of c-
KIT in 17/41 (41.4%) children with CBF-AML: 12/28 (43%) were mutated in RUNX1-
RUNX1T1-rearranged children, as compared with 5/13 (38.5%) in inv(16). Both studies did 
not find any statistical influence of c-KIT mutation on patient outcome. In addition, Pollard 
et al (4) analyzed the mutation status of 203 children with CBF-AML finding c-KIT 
mutation in 19/94 t(8;21) patients and in 19/71 carrying inv(16). Notwithstanding the large 
sample size, the results did not reach significance for survival parameters. These findings 
are in contrast with our data and with the data published by Shimada et colleagues 
7
 who 
screened 46 t(8;21) children for c-KIT mutations. Significant differences between patients 
with or without c-KIT mutations were observed in the 4-year OS (50.0% versus 97.4%, p = 
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0.001), disease-free survival (37.5% versus 94.7%, p < 0.001) and relapse rate (47.0% 
versus 2.7%, p < 0.001). In view of our data on the incidence and the prognostic impact of 
c-KIT mutations, we believe that t(8;21) and inv(16)/t(16;16) patients should be analyzed 
separately. In particular, among our c-KIT-mutated patients who experienced relapse we 
observed that 5 out of 5 t(8;21) patients were dead, whereas 5 out of the 7 children 
RUNX1-RUNX1T1-positive non c-KIT mutated who relapsed were rescued by second-line 
treatment. These findings provide the rationale for considering c-KIT mutations as an 
additional genetic marker to be taken into account in patient stratification. The nature of c-
KIT mutations offers an attractive target for tyrosine kinase inhibitors. c-KIT mutations are 
associated with a gain of function that induces receptor hyperactivation in response to SCF 
stimulation, and this leads to a loss of growth factor dependency, increased proliferation 
and resistance to apoptosis
9
. Notably, different drugs have been developed against tyrosine 
kinases. Imatinib has been demonstrated to be suitable for mutations at exon 8 and exon 17 
involving specifically the codon N822, but not for mutations involving codon D816, which 
can be successfully targeted with other drugs, such as dasatinib and midostaurin. However, 
the utility of receptor tyrosine kinase inhibitors for patients with CBF-AML and c-KIT 
mutations remains to be further evaluated.  
Nowadays, the multistep model of leukemogenesis is widely accepted: class-II 
mutations affecting genes that impair hematopoietic differentiation, such as RUNX1-
RUNTX1 and CBFB-MYH11, cooperate with class-I mutations involving genes, such as 
KIT, FLT3 and RAS, whose mutation leads to increased cell proliferation and survival. 
Expression of RUNX1 and CBF-β appears to be essential for the development of normal 
hematopoiesis, since knockout of these genes in animal models leads to lack of definitive 
hematopoiesis and embryonic animal death (10). Nevertheless, in vitro and in vivo studies 
have shown that isolated CBF fusion transcripts were not sufficient to induce 
leukemogenesis, additional events being necessary for overt leukemia occurrence
11-13
. 
Recently, 2 different studies reported that patients with t(8;21) treated with a lipid 
formulation of daunorubicin during induction therapy had a better outcome than those 
treated with idarubicin
14
, and that a second induction course with high-dose cytarabine and 
mitoxantrone is beneficial for patients with t(8,21)
15
. It remains to be proved whether the 
advantage of both these therapies mainly concentrates in patients harboring the c-KIT 
mutation.  
In summary, we characterized the incidence of c-KIT mutations in CBF rearranged 
patients treated with the AIEOP AML2002/01 protocol; it was 25% and 18.5% for children 
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carrying t(8;21) and inv(16)/ t(16;16), respectively. We document that the detection of a c-
KIT mutation at diagnosis in t(8;21)-positive patients confers a detrimental prognostic 
impact. These patients might benefit from a targeted therapy with tyrosine kinase 
inhibitors. 
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SUPPLEMENTARY INFORMATION 
 
Table 1S. Primers used for the screening of c-KIT mutations. 
 
 
Table 2S. Clinical patient’s features. 
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LETTER TO THE EDITOR 
Disease relapse still remains the most important cause of treatment failure in 
childhood acute myeloid leukemia (AML). Molecular monitoring of response to treatment 
by minimal residual disease (MRD) provides remarkable information, widely used  to 
tailor treatment in childhood acute lymphoblastic leukemia
1–3
. On the contrary, prognostic 
relevance of MRD in pediatric AML has been only recently proposed and needs to be 
further investigated and confirmed
4–6
. So far, the prognostic impact of the quality of 
response measured by flow-cytometry after induction and consolidation therapy has been 
shown to provide independent prognostic information in pediatric AML,
5
 able to permit a 
refinement of risk stratification and to potentially improve AML patient outcome. Intense 
efforts have been devoted to the development of methods able to measure residual AML 
burden in support to flow-cytometry, and fusion transcript detection, which is indubitably 
useful in patient stratification at diagnosis
7
, is currently under evaluation as suitable MRD 
marker to predict relapse in AML
5
. 
t(8;21)(q22;q22)RUNX1-RUNX1T1 and inv(16)(p13q22)CBFB-MYH11 are 
recurrent somatic lesions detected in about 20% of pediatric AML at diagnosis
8
. In the 
AIEOP AML 2002/01 protocol, all patients carrying these abnormalities achieved 
morphological complete remission (CR) after the first induction course with idarubicin, 
cytarabine and etoposide (ICE) and were grouped as a unique subgroup called standard risk 
(SR). These children were given, after 2 courses of ICE induction therapy, three post-
remissional courses of high-dose cytosine-arabinoside either in combination with etoposide 
(AVE cycle), or Mitoxantrone (HAM cycle) or administered alone (High dose Ara-c)
7
. A 
larger than expected proportion of patients carrying either t(8;21) or inv(16) relapsed, this 
leading to a 8-year probability of event-free survival of 63%. Although many of the 
relapsing patients were rescued by means of allogeneic hematopoietic stem cell 
transplantation (HSCT)
8
, there is need to identify factors able to predict patients who might 
not respond to conventional chemotherapy to improve their outcome 
9–11
. In this 
retrospective study, we analyzed the role of MRD monitored by the absolute quantification 
of CBF fusion transcripts early during/after induction treatment, in order to assess its 
prognostic value in SR childhood AML. We enrolled 76 of the 99 children assigned to the 
SR group in the AIEOP AML 2002/01 Protocol
8
: 49 carried the t(8;21), 26 inv(16), and 
one t(16;16) (see Table 1 for details). MRD measurement on bone marrow samples 
collected at time of diagnosis and after each of the 2 courses of ICE induction 
chemotherapy was analyzed. It was not possible to study the remaining 23 SR patients due 
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to insufficient RNA extracted from cells collected after induction courses, but the outcome 
of patients who were or were not included in the study was comparable (data not shown). 
We used the Real-time quantitative RQ-PCR (Ipsogene FusionQuant® kit for absolute 
quantification of fusions on the ABI 7900HD -Applied biosystems) to detect RUNX1-
RUNX1T1 and CBFB-MYH11 fusions expression following manufacturer’s guideline for 
normalization (with ABL gene) and standard curve method for quantification (10
-5
 standard 
curve sensitivity by using plasmid serial dilutions already included in the kit)
12,13
. 
 
 
Table 1. Patient’s clinical characteristics.  
For the t(8;21)-rearranged patients, we found a mean number of RUNX1-RUNX1T1 
fusion transcript copies at diagnosis of 643,466 (range from 56,752 to 3,387,522); it 
decreased to 190,741 mean copies after the I ICE course (range from 11 to 3,062,045), and 
to 44,671 after the II ICE (range from 0 to 1,671,638). To evaluate the impact of MRD 
levels measured as copies number during sequential monitoring, the Mantel-Byar test was 
used to calculate the cumulative incidence of relapse (CIR). We grouped patients in 
quartiles for copy number measured at diagnosis, after the first and second ICE course. The 
number of transcript copies at diagnosis, or after induction therapy did not correlate with 
the probability of both survival and the CIR. 
We then considered the logarithmic reduction of MRD after ICE I and II courses 
calculated with respect to values of copies number of transcript found at diagnosis for each 
patient (Table 1S). We subdivided patients in three Log-reduction groups: patients who 
reduced MRD less than 2 Log, between 2 and 3 Log, and those who reduced more than 3 
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Log in order to investigate whether this distribution into groups for MRD reduction was 
able to predict a different relapse risk. We interestingly found that 21 (43%)  out of the 49 
t(8;21) patients enrolled had a slow clearance of blasts after I ICE (< 2 Log with respect to 
diagnosis), and, at the end of the II ICE course, 10 of them still had a MRD reduction 
lower than 2 Log. These slow-responding t(8;21) patients at the end of the 2 induction 
courses had a worse prognosis when compared to patients who reduced MRD more than 3 
Log (patients who reduced less than 2 Log showed a 10-year OS of only 58.3% compared 
to 85.6% of patients who reduced more than 3 Log, p = 0.2, Figure 1).  
 
Figure 1. Overall Survival (OS) in RUNX1-RUNX1T1 patients subdivided into three classes of MRD Log 
reduction after two induction courses 
 
Next, we investigated if MRD might influence the risk of relapse. Nine out of the 
49 patients with t(8;21) relapsed at a median time of 225 days (range 76 to 469) from 
diagnosis: 7 out of the 9 relapsed t(8;21) patients reduced MRD less than 2 Log after I ICE, 
and 5 of these 9 relapsed patients still reduced MRD less than 2 Log at the end of the II 
induction course. The 10-year CIR of these patients after the two induction courses was 
significantly higher (50%) than that of patients with a MRD reduction greater than 2 Log 
(17% for 2-3 Log MRD reduction, and 9% for MRD Log reduction >3; Figure 2A I ICE 
p=0.02; 1B II ICE p=0.004). In univariate analysis both MRD log-reduction after induction 
therapy and white blood cell (WBC) count at diagnosis >100,000, as recently reported
8
, 
were significant independent factors predicting leukemia relapse; however, they were not 
confirmed in multivariate analysis, probably due to the limited sample size analyzed. In 
view of these data, we show that monitoring of molecular MRD levels is instrumental to 
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predict the risk of relapse for t(8;21)-rearranged patients, thus providing important 
prognostic information for the therapeutic management of these children. 
 
Figure 2. Cumulative Incidence of Relapse (CIR) in patients with RUNX1-RUNX1T1 (A) and CBFB-MYH11 
(B) subdivided into different subgroups according to MRD Log reduction after I ICE and II ICE. 
We then considered inv(16)-rearranged patients and performed similar analyses for 
the 27 patients enrolled. These patients showed a mean number of transcript copies at 
diagnosis of 143,015 (range from 102 to 582,426), which decreased to 631 (range from 0 to 
3,726) after the I ICE, and to 190 (range from 0 to 686) after the II ICE course, 
respectively. We evaluated if the copy number of fusion transcripts distributed in quartiles 
found in BM of patients at diagnosis, and at the end of the two ICE courses may have a 
prognostic value, but no significant differences were identified neither for CIR nor for OS 
in inv(16) rearranged patients (Figure 1S). Furthermore, by using the Log MRD reduction 
distribution, we found that 21/27 patients (78%) after the I ICE, and 24/27 (89%) after the 
II ICE achieved a MRD reduction greater than 2 Log. At time of last follow-up, 6/27 
patients had relapsed; among them, we documented that MRD was reduced more than 2 
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Log. We conclude that the CBFB-MYH11 AML showed in most cases a rapid clearance of 
blasts after induction therapy. Thus, early MRD monitoring does not seem to be useful for 
predicting relapse occurrence (Figure 2B, not significant at 10 years).  
Through this analysis, we document that among pediatric Core Binding Factor-
rearranged AML two different patterns of molecular response after induction therapy with 
a different capacity of predicting relapse can be identified. In particular, we found that 
monitoring of MRD levels after induction provides a reliable prognostic parameter 
exclusively for the RUNX1-RUNX1T1-rearranged patients. These data confirm the clinical 
usefulness of monitoring MRD levels reported in a recent study on adults with RUNX1-
RUNX1T1 AML
14
, although this report differs from our analysis in both timing (after 2 
courses of consolidation therapy) and levels of MRD (3 log reduction) cut-off suggested to 
predict relapse.  
In view of these results, we propose a novel MRD-directed risk stratification and 
treatment of t(8;21) slow-responders to induction therapy. These children can be identified 
early during treatment and, in light of their high risk of relapse, can be considered 
candidates to more aggressive therapies, even including allogeneic HSCT. We, thus, 
propose that RQ-PCR MRD monitoring complemented with the flow-cytometry MRD
14
 
data might be incorporated directly into clinical practice of the RUNX1-RUNX1T1 risk 
class attribution, whereas further studies on extended MRD monitoring for CBFB-MYH11 
rearranged patients are desirable to identify a possible role in predicting the risk of late 
relapse. 
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ABSTRACT 
Purpose. Recurrent molecular markers in AML have been routinely used for risk 
assessment at diagnosis, whereas their post-treatment monitoring still represents a debated 
issue in pediatric patients’ clinical management.  
Experimental design. We evaluated the prognostic value and the biological impact 
of molecular minimal residual disease (MRD) after induction course I and II and of the 
Allelic Ratio (AR) at diagnosis of FLT3-internal-tandem-duplication (ITD) in childhood 
AML. We retrospectively screened 494 children with de novo AML for FLT3-ITD 
mutation enrolled in the AIEOP-AML 2002/01 protocol. We correlated these parameters 
with event free survival (EFS), relapse, and gene expression profile (GEP).  
Results. Fifty-four patients harboured FLT3-ITD. 51% had high-ITD-AR at 
diagnosis and worse EFS (19.2% versus 63.5% for low-ITD-AR, p<0.05). 41% of children 
with higher levels of MRD after the I induction course had worse EFS (22.2% versus 
59.4%, p<0.05). GEP showed that patients with high-ITD-AR or persistent MRD had 
different expression profiles, and that most of deregulated genes were involved in 
methylation and acetylation. Moreover, ITD-mutation sustained high CyclinA1 expression, 
a novel unfavourable prognostic factor (EFS 20.3% versus 51.2% in low CyclinA1 
expression, p<0.01), principally by triggering the B-MYB oncogenic network.  
Conclusions. These findings highlight that ITD-AR levels and MRD after I 
induction course should be considered in planning clinical post-induction management of 
FLT3-ITD patients to improve their outcome. The evaluation of these parameters suggest 
different transcriptional activation of epigenetic and oncogenic profiles to be targeted with 
novel therapeutic approaches in order to overcome variability in outcome among FLT3-
ITD patients.  
INTRODUCTION 
Genetic characterization of acute myeloid leukemia (AML) has led to the 
identification of  a great number of molecular markers that are currently used to guide the 
diagnosis and the clinical management of pediatric patients.
1–4 
However,
 
there has been 
minimal improvement in the outcome of AML, and relapse remains a major cause of 
treatment failure despite the genetic risk assignment.
5
 These molecular markers have 
further split AML into small patients subgroups for which no studies, providing a more 
objective assessment of treatment response and targeted therapy, have been reported to 
date. The monitoring of minimal residual disease (MRD) can be consider one of the most 
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sensitive approach to detect an early response kinetic to distinguish patients with different 
risk within the same genetic group, predict relapse and direct pre-emptive MRD-directed 
therapy decisions.
6
 
 The Fms-like tyrosine kinase 3 (FLT3) is a class III receptor kinase that is 
normally expressed by hematopoietic stem cells and progenitor cells and is down-regulated 
at later differentiation stages, driving early steps of cell proliferation, survival and myeloid 
lineage differentiation.
7
 Abnormalities of the FLT3 gene occur frequently in AML as a 
result of internal tandem duplication (ITD) of the juxtamembrane domain-coding sequence 
in frame with the rest of the gene, or as point mutation within the activation loop domain 
(FLT3-ALM). The mutated FLT3 gene results in constitutive activation of the kinase 
domain. In childhood AML, the activating mutations of FLT3 occur in 10-15% of patients: 
two-thirds of these harbor ITD while one-third FLT3-ALM 
8–12
.Patients with FLT3-ALM 
have a prognosis comparable to that of patients without FLT3 mutations;
12
 on the contrary, 
FLT3-ITD patients have poor prognosis, mostly for high risk of disease recurrence.
12
 
Efforts have been spent in the past decade to identify molecularly adapted 
treatments, such as those targeting FLT3 activity, and, although some encouraging results 
have been reported in adults, responses are incomplete and mechanisms of resistance often 
occur.
13
 The degree of reduction of the leukemia-cell burden following the initial courses 
of induction therapy, as well as the time required to achieve complete remission have been 
demonstrated in adults to independently impact on prognosis.
14
 To date, it remains debated 
whether the FLT3-ITD mutational status affects outcome and whether the specific 
characteristic of the FLT3-ITD mutation, such as the size of the ITD, the number of clones 
and the allelic ratio (AR), are prognostically relevant factors in children with AML.
15,16
  
Furthermore, up to now, the constitutive kinase activity has been commonly 
targeted with several drugs with a limited clinical success, suggesting that inhibition of 
other factors contributing to the malignant phenotype is probably required. Here, we report 
the results of a comprehensive study in a pediatric AML cohort aimed at the 
characterization of FLT3-ITD mutation and its impact on outcome.  We investigated the 
role of the AR at diagnosis. We confirmed the suitability of FLT3-ITD aberration as a 
sensitive molecular marker for MRD monitoring during therapy. Finally, we performed 
gene expression analysis with the aim of bringing further insight into the biology of the 
FLT3-ITD mutation and its role in explaining the low rate of response to therapy that is 
observed in a large proportion of FLT3-ITD patients. 
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STUDY DESIGN  
Patient samples. Patients with de novo AML (N=494) other than acute 
promyelocytic leukemia, aged 0-18 years, newly diagnosed between 2002 and 2014 in one 
of the centers associated with AIEOP (Associazione Italiana Ematologia Oncologia 
Pediatrica) were all treated according to the same protocol AML 2002/01 and all the FLT3-
ITD mutated patients were considered  in this study.
5
 In accordance with the Declaration of 
Helsinki, informed consent, was obtained from patient parents or legal guardians. FAB 
morphological classification, immunophenotypic analysis and molecular characterization 
were centrally reviewed at the laboratory of Pediatric Hematology of the University 
Hospital in Padova, Italy. Follow up samples of BM from FLT3-ITD-mutated patients, 
whenever available after routine analysis, were collected for RNA extraction and MRD 
analysis at fixed time points: at the end of the first (29 patients) and second (33 patients) 
course of induction therapy (ICE courses, consisting of a combination of idarubicin, 
cytarabine and etoposide), and  before bone marrow transplantation for patients who 
underwent to HSCT as defined for the high risk patients by the AML 2002/01 protocol (for 
25 patients FLT3-ITD who were transplanted in first CR the bone marrow 1 week before 
transplantation was available and collected for RNA extraction). Details on transplantation 
procedure and supportive care have been previously described.
17
 Bone marrow RNA from 
85 patients with de novo AML at diagnosis were used for gene expression analysis. This 
cohort comprised 71 patients harboring recurrent AML abnormalities (CBF, MLL, NPM1, 
DEK-CAN, and negative for recurrent molecular aberrancies) and 14 patients with FLT3-
ITD. 
FLT3-ITD PCR and Allelic Ratio (ITD-AR) determination. Genomic DNA and 
total RNA were extracted from BM samples at diagnosis using the Gentra Puregene Cell 
kit (QIAGEN) and TRIzol (Invitrogen, Carlsbad, CA) as previously described
18
. Reverse 
transcription was performed using the SuperScript II First Strand Synthesis System 
(Invitrogen). FLT3-ITD screening was performed either on cDNA (N=53, one was not 
available) or on DNA (N=37) and analyzed with the GeneScan® Analysis Software (see 
detailed method in supplementary files). We considered the cut off >0.51 as high-ITD-AR 
for survival analysis 
15,19
. 
Sanger sequencing and Quantitative RQ-PCR. Assessment of FLT3-ITD 
transcript levels was performed with a mutation-patient specific RQ-PCR assay. Briefly, 
FLT3-ITD was sequenced in order to identify and characterize the sequence of the 
duplication with the 3.1 BigDye Terminator Cycle Sequencing Kit (Applied Biosystems, 
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Foster City, CA) and analyzed on the 3500DX Genetic Analyzer (Applied Biosystems), 
according to the manufacturer's instructions. Assessment of FLT3-ITD transcript levels was 
performed on an ABI 7900HD platform (Applied Biosystems) using a Taqman Universal 
Master Mix (Applied Biosystems). The forward primer and the probe were common while, 
the reverse primer was designed using Primer Express software (Applied Biosystems) to 
uniquely select the joining region between the wild-type sequence and the beginning of 
FLT3-ITD, therefore being specific for each patient. All samples were tested in triplicate. 
Standard curves for FLT3-ITD and GUSB were established by amplifying a 10-fold serial 
dilution of target cDNA obtained at diagnosis. MRD levels were normalized to GUSB and 
then measured relative to FLT3-ITD transcript levels at diagnosis. RNA in follow-up 
samples with housekeeping gene GUSB Ct >30 were excluded from the study. Expression 
of CyclinA1 were measured by RQ-PCR using the Sybr Green PCR master mix (Applied 
Biosystems) and normalized on GUSB using the 2^-DDCt method (see supplementary 
information for primer sequences). 
Gene expression analysis and gene functional enrichment analysis. Bone 
marrow RNA from 85 patients with de novo AML at diagnosis were hybridized on the 
GeneChip® Human Transcriptome Array 2.0 (Affymetrix), as described in supplementary 
methods. Microarray expression data are available in the U.S. National Center for 
Biotechnology Information Gene Expression Omnibus (GEO) database under accession 
number GSE74183.  
Multiparametric flow cytometry (MFC). Immunophenotype was performed at 
diagnosis and during follow-up on erythrocyte-lysed whole BM by MFC, using a direct 
immunofluorescence technique with six-color combinations of monoclonal antibodies 
(MoAbs). Briefly, in each analysis, 0.5 x 10
6
 cells were incubated for 10 min with the 
appropriate combination of MoAbs directly conjugated with FITC, PE, PE-CY5, PE-CY7, 
APC, APC-CY7. Samples were subsequently lysed using 3 ml of NH4Cl, then washed in 
phosphate-buffered saline (PBS), and re-suspended in 0.5 ml of PBS. Intracellular staining 
was performed by a two-step fixation and permeabilization procedure using a commercial 
kit (Caltag Laboratories, Fix&PermTM, San Francisco, CA) according to the 
manufacturer’s instructions. Leukemia cells were identified using an immunological gate 
based on CD45 expression associated with physical parameter.
20
 Leukemia associated 
immunophenotypes (LAIPs), defined by the presence of antigens and flow-cytometry 
physical abnormalities, absent or very infrequent in normal or regenerating BM, has been 
created for each patient at diagnosis and used during follow up for MRD monitoring. For 
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the immunophenotypic characterization of diagnoses 30,000 events for each tube were 
collected. For MRD detection by MFC, at least 3 x 10
5
 ungated events were collected and 
analyzed. The minimum target sensitivity for quantifying MRD was defined as the ability 
to detect 50 clustered MRD events in 5 x 10
5
 total cellular events (0.01%). Six-color MFC 
was performed using a BD CANTO II flow cytometer (Becton Dickinson, San Jose, CA). 
Statistical methods. Probability of survival was estimated using the Kaplan-Meier 
method and compared between groups through the log-rank test. Event-Free Survival 
(EFS) was calculated from date of diagnosis to last follow-up or first event (failure to 
achieve remission, relapse, death, whichever occurs first). The Mantel-Byar test was used 
to calculate the cumulative incidence of relapse (CIR). EFS and CIR for patients given 
HSCT were calculated from the day of transplantation. Significance was tested using Chi-
square test and Fischer’s exact test. Pearson correlation, Bland-Altman analysis and 
Spearman’s rank correlation tests were also used. Variables having a significant p-value in 
univariate analysis were included in a multivariate analysis performed using the Cox 
proportional regression model. A p value ≤0.05 was considered to be statistically 
significant. 
RESULTS 
Characteristics of the FLT3-ITD mutation. FLT3-ITD has already been reported 
to be an adverse prognostic factor in AML.
8,9,12,21,22
 Molecular screening for FLT3-ITD 
was performed in 494 patients with de novo AML. Fifty-four patients were found to harbor 
ITD (Table1): these children were older (11.5 versus 7.3 years, p<0.001) and had a higher 
WBC at diagnosis (93 versus 46x10
9
 WBC/L, p<0.01) than those who did not carry this 
abnormality.
12
 FLT3-ITD occurred preferentially in AML without complex karyotype 
(84.7%),
23,24
 and more frequently in patients who did not achieve CR at the end of first 
induction (59.3%). The ITD length ranged from 18 to 126 base pairs and was not 
predictive of outcome (data not shown). Forty-five patients were found at diagnosis with a 
single ITD, while 9 had either 2 or 3 ITDs (Table1S). The clinical significance of the 
presence of multiple ITD is still debated
9,16
, although in our cohort no difference in 
survival was found (data not shown)
16
. ITD mutation occurred within exon 14 of the FLT3 
gene for all patients analyzed except 6, in whom the duplication interested exon 14 and part 
of exon 15. 13 had a perfect duplication, while 22 had also an insertion of 3 to 15 random 
nucleotides maintaining the frame. A common region internal to all the ITDs that covered 
from aminoacid 591 to 597 is defined (Figure1S)
16,25
. 
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Clinical significance of the FLT3-ITD Allelic Ratio. Patient characteristics taken 
according to ITD-AR measured on cDNA (N=53) revealed that children with high-ITD-
AR (>0.51)
15,19
 had an increased WBC at diagnosis in comparison to patients with low-
ITD-AR (<0.51) (123 versus 77x10^9/L, p<0.05), and carried more frequently a second 
genetic event, such as a recurrent translocation (55% versus 17%, p<0.01), whereas the 
percentage of blasts at diagnosis did not significantly influence the AR.
5,10,26
 FLT3-ITD-
AR showed concordance when measured on the 37 patients for whom we had both cDNA 
and DNA (83%, R=0.68, p<0.001, Table1S). Survival analyses at 3 years on this cohort 
revealed that high-ITD-AR patients had a worse EFS compared to those with low-ITD-AR 
when calculated on cDNA (19.2% versus 63.5%, p<0.05, Figure1A), whereas AR 
performed on DNA was never prognostically significant (Figure1B). This latter 
observation supports the concept that expression of the mutation is more important than 
genomic bulk architecture at diagnosis. The incidence of relapse was not influenced by 
ITD-AR either on cDNA or DNA (CIR not significant, Figure2SAB), mainly because the 
most frequent event, occurred in patients with a higher-AR, was the failure to achieve CR 
(No CR = 12/29 (41%) vs 2/24 (8%), p<0.05, Table2). 
 
 
Figure 1. Clinical outcome for FLT3-ITD mutated patients with allelic ratio (ITD/wild type) higher or lower 
than 0.51 executed for RNA or DNA. A) Event-Free Survival (by AR on cDNA). B) Event-Free Survival (by 
AR on DNA). Abbreviations: p = p value, N= number of patients, E = number of events, SE = standard error 
Impact of MRD after first and second induction courses and before HSCT. It 
has been reported that FLT3-ITD can shift or disappear in the time period elapsing between 
diagnosis and relapse.
27–29
 This phenomenon is due to the outgrowth, owing to treatment, 
of different clones that evolve in a bulk leukemia.
27–29
 In our cohort, 16 out of 19 (84%) 
paired diagnosis-relapse bone marrow samples maintained the same ITD mutation,
27–29
 
supporting its use as molecular biomarker. To definitely establish the use of FLT3-ITD as a 
bona fide biomarker, we confirmed its specificity and sensibility by measuring the MRD 
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FLT3-ITD 
  
AML 
  
p value  
  
N 54 440   
Age      < 0.0001* 
<2 yrs  1 (1.8%) 115 (26.1%)   
2-10 yrs 17 (31.5%) 166 (37.7%)   
>10 yrs  36 (66.7%) 159 (36.2%)   
WBC count (x10^9/L)      < 0.0001* 
<10 7 (13.2%) 160 (36.4%)   
10-99 23 (43.4%) 220 (50%)   
>100 23 (43.4%) 60 (13.6%)   
N/A 1 0   
FAB     0.26 
M0 5 (9.3%) 31 (7%)   
M1 8 (14.8%) 77 (17.5%)   
M2 11 (20.4) 83 (18.9%)   
M4 13 (24%) 73 (16.6%)   
M5 9 (16.7%) 109 (24.8%)   
M6 0 5 (1.1%)   
M7 1 (1.8%) 43 (9.8%)   
N/A 7 (13%) 19 (4.3%)   
Complex Karyotype     0.01* 
YES 7 (15%) 25 (5.7%)   
NO 39 (85%) 414 (94.3%)   
N/A 8 1   
Complete Remission      < 0.0001* 
YES 32 (59.3%) 389 (88.4%)   
Relapse      0.39 
YES 16 (29.6%) 107 (24.3%)   
Table 1. Characteristics of FLT3-ITD AML patients. Abbreviations: yrs = years; WBC= white blood cell; 
N/A not available; * p<0.05. 
by RQ-PCR of the additional fusion gene when present. We selected 8 patients with a 
concomitant fusion gene, such as the t(5;11)/NUP98-NSD1 (N=4), the t(6;9)/DEK-CAN 
(N=3) and the t(8;21)/AML1-ETO (N=1), and measured the MRD levels at the same time 
points (after ICE I and II, and pre HSCT). MRD levels by FLT3-ITD or by translocation 
significantly correlated (R=0.7, p<0.05) confirming that FLT3-ITD can be considered a 
reliable molecular MRD marker (data not shown). 
FLT3-ITD MRD levels reduction compared to diagnosis by RQ-PCR after the first 
(N=29) and the second (N=33) ICE were analyzed. MRD reduction after the first ICE was 
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at least 2 logs for 59% of patients (17/29, Table2). Among the 12 patients that presented an 
MRD reduction less than 2 logs after the first ICE 66.7% relapsed, whereas only 23.5% of 
those who had > 2logs reduction relapsed (p<0.05). Finally, patients who reduced MRD 
levels less than 2 logs had a significantly worse EFS and higher CIR compared to those 
who reduced more than 2 logs (EFS: 22.2% versus 59.4 %, p<0.05; CIR: 68.7% versus 
24.3%, p<0.05, Figure2A and Figure3SA). These results indicate that molecular levels of 
MRD after the first ICE can predict patients outcome anticipating a higher risk of relapse. 
At the end of the second ICE most of patients had a better disease clearance (26/33 reduced 
MRD >2logs), however the incidence of relapse did not reach statistical significance (EFS 
50.5% versus 14.3%, p<0.05; CIR 71.5% versus 43.5%, ns, Figure3SAB). Among the 24 
patients eligible to receive HSCT in first CR,
23
 the 5 who reduced MRD less than 3 logs 
showed a trend for a worse outcome when compared to those who reduced more than 3 
logs after receiving HSCT (EFS: 40.0% versus 72.9%; CIR: 60.0% versus 27.1%, 
Figure4SAB).  
 
Table 2. Characteristics of high (>0.51) and low (<0.51) ITD-AR patients on cDNA and of patients with 
MRD reduction < or > than 2logs. Abbreviations: WBC= white blood cell; CR= complete remission; 
*p<0.05. 
 
High  
ITD-AR 
Low 
 ITD-AR 
p value 
MRD Red 
< 2logs 
MRD Red 
> 2logs 
p value N=29 N=24  N=12  N=17  
Age mean (years) 11.6 10.2 0.36 13.2 10.7 0.053 
WBC mean 
(x10
^9
/L) 
123 77 <0.05* 105 55 0.16 
No CR 12 (41%) 2 (8%) <0.05* 3 (25%) 1 (6%) 0.27 
Relapse 13 (45%) 9 (37%) 0.77 8 (66.7%) 4 (23.5%) <0.05* 
Associated 
translocation 
16 (55%) 4 (17%) <0.05* 5 (42%) 4 (23%) 0.42 
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Figure 2. Clinical outcome for patients harboring FLT3-ITD mutation that had a minimal residual disease 
(MRD) reduction greater (>) or lower (<) than 2 logs after the first induction cycle (ICE). The Figure reports 
data after the first cycle of therapy for A) Event-Free Survival (EFS), B) Cumulative Incidence of relapse. 
Abbreviation: p = p value, N= number of patients, E = number of events, SE = standard error. 
Minimal residual disease evaluation by multiparametric flow cytometry 
(MFC). Twenty-four follow-up bone marrow samples from FLT3-ITD mutated patients 
were evaluated in parallel with both Multicolour Flow Citometry (MFC) and RQ-PCR 
analysis at the same time points during treatment. The analysis showed positive 
concordance between MFC and PCR results (R=0.5, p<0.01, Figure5SAB). To compare 
the MFC-MRD and PCR-MRD methods more specifically, the Bland-Altman analysis was 
used.
30
 The average of the differences between the two methods was 0.27; thus, the two 
methods can be considered comparable. Moreover, the difference between measurements 
using these two methods lies within the limits of agreement more than 95% of the time. 
Gene expression profiles of high and low-ITD-AR patients. To gain further 
insight into the role of FLT3-ITD in AML, we analyzed the gene expression profiles of 14 
FLT3-ITD positive patients. We found 154 transcript clusters (coding genes, lncRNA, 
microRNA, pseudogenes, rRNA) differentially expressed between FLT3-ITD positive and 
the rest of AML patients (Figure3A and Table2S). GEP by considering coding genes 
confirmed ENPP2, CD180, CD86, SORT1, and IDH1, which were up-regulated in FLT3-
ITD mutated patients, most of them previously described in other reports as confirmed by 
GSEA (Figure3B)
31,32
. This new platform revealed also a new set of transcripts (N=86) 
such as lncRNAs and pseudogenes to be further studied within FLT3-ITD patients. 
Expression profiles revealed that FLT3-ITD patients clustered according to their ITD-AR 
status (low versus high, Figure3C). We found 409 transcript clusters with significant 
different expression between the two sample groups (Table3SA). Among the top-ranking 
over-expressed genes there was a new methyltransferase METTL7B as well as CyclinA1, 
FOSB and JUN. By GSEA, we found that the main pathways positively enriched in high-
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ITD-AR were those connected with H3K27 tri-methylation (Table3SB), which is tightly 
associated with inactivation of gene promoter. Among the down-regulated genes there was 
KMT2A, a H3K4 methyltransferase, which mediate chromatin modifications associated 
with epigenetic transcriptional activation. Nonetheless, in high ITD-AR there were down-
regulated genes documented to be tumor suppressor (such as MN1, TP53INP1, MIR181B1, 
by TSGene Database). 
 
Figure 3. Gene expression profiles of 14 FLT3-ITD positive patients. A) Heat map of hierarchical clustering 
by gene expression signature. In orange are represented mutated patients, while in green other AML 
including patients with core-binding factor aberrations, MLL rearrangements, NPM1 abnormalities, 
t(6;9)(p23;q34)DEK-NUP214 and negative for known recurrent genetic abnormalities previously described. 
B) Enrichment plots from Gene Set Enrichment Analysis (GSEA). Plots contain profiles of the running 
enrichment scores (ES) and positions of FLT3-ITD related gene set members (indicated by black vertical 
lines) on the rank ordered list in GSEA. In both plots, we observe a positive enrichment in leukemia samples 
harboring FLT3-ITD mutations gene sets. C) Heat map of hierarchical clustering of patients with high versus 
low AR (p<0.05). In green are represented patients with AR <0.51 (low), while in orange patients with AR 
>0.51 (high). D) Heat map of hierarchical clustering by gene expression of 5 FLT3-ITD positive patients with 
good or poor minimal molecular disease (MRD) reduction defined as > or < than 2 logs from diagnosis at the 
end of induction. In red and blue are represented poor and good prognosis patients, respectively.  
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In addition, Gene Ontology (GO) analysis showed enrichment in biological processes 
involving nucleosome assembly and DNA organization (p<0.01, Table3SC). Interestingly, 
multivariate analysis showed that high ITD-AR levels significantly contributed to the 
prognosis of patients with AML (p<0.05) more than CyclinA1 or age, sex and WBC 
(Table5S).  
Gene expression profiles of FLT3-ITD patients by MRD levels. In an attempt to 
explain the different response to induction treatment, we analyzed the FLT3-ITD-mutated 
AML cohort dividing patients according to their MRD clearance (< or > 2logs from 
diagnosis to completion of ICE, defined as poor or good responders, respectively, 
Figure3D and Table4SA). Between the two sample groups, 161 transcript clusters with 
significant differential expression were identified. Among the top ranking over-expressed 
genes there was CyclinA1, this finding supporting the notion that cell cycle is the main 
actor in drug response,
33,34
 and two oncomirs, MIR21 and MIR221, associated with drug 
resistance.
35,36
 These results suggested that reduced response to induction might be 
sustained by a different transcriptional program already evident at the time of diagnosis. 
GSEA was then applied revealing a significant positive enrichment in resistance to drugs 
and, interestingly, in histone acetylation (Table4SB).  
Remarkably, CyclinA1 was significantly overexpressed in FLT3-ITD-mutated 
patients compared to the rest of AML patients (Figure4A, p<0.05), in high-ITD-AR 
compared to low-ITD-AR patients (Figure4B, p<0.05) and in poor versus good responders 
(Figure4C, p<0.05). We enlarged the cohort to 48 FLT3-ITD patients for CyclinA1 
expression by RQ-PCR (Figure4D). Survival analysis dividing patients according to the 
mean CyclinA1 expression value revealed that higher CyclinA1 expression correlated with 
poorer EFS (20.3% versus 51.2%, p<0.05, Figure4E). Twenty over 24 patients with higher 
CyclinA1 expression were also high-ITD-AR, while there were only 8/24 among the low 
CyclinA1 expressing group (p<0.05). It was previously documented that the 
CyclinA1/CDK2 complex phosphorylates B-MYB
37
 and we found that its signature 
(deposited data of the B-MYB transcriptional network
38
) when applied to the FLT3-ITD-
positive patients clustered the high-ITD-AR patients from the low-ITD-AR patients 
(Figure4F).  
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Figure 4. CyclinA1 in FLT3-ITD patients. A) Box Plot of CyclinA1 (CCNA1) expression in FLT3-ITD 
patients versus patients with other AML variants (p<0.05). B) Box Plot of CyclinA1 expression in High-ITD-
AR versus Low-ITD-AR (p<0.05) and C) Box Plot of CyclinA1 expression in Poor versus Good prognosis 
FLT3-ITD patients as assessed by MRD monitoring after induction therapy. D) RQ-PCR expression, 
calculated with 2^-DDCt of CyclinA1 in FLT3-ITD mutated patients compared to HBM (RQ=1). E) Event-
Free Survival for AML patients with high (N = 24) or low (N = 24) level (< or > than median value) of 
CyclinA1 expression. F) Heat map of hierarchical clustering (up) and PCA analysis (low) of 14 FLT3-ITD 
positive patients using B-MYB signature.(
38)
 In green are represented patients with AR <0.51 (low), while in 
orange patients with AR >0.51 (high). Abbreviations: RQ = relative quantity, PCA = Principal component 
analysis. 
DISCUSSION 
Recurrent molecular markers have been discovered in AML in the last 3 decades 
and are now routinely used for risk stratification at diagnosis within clinical protocols. In 
pediatric AML, post-treatment monitoring of these abnormalities has been rarely used in 
the clinical management of patients. Up to now, which molecular marker is suitable to be 
followed during therapy and used to refine remission definition and tailor treatment is still 
unknown. MRD, largely used in acute lymphoblastic leukemia and acute promyelocytic 
leukemia
39,40
, is gaining popularity also in AML, and its monitoring is mainly based on 
MFC
41
, given the lack of large studies on molecular MRD measurements
42
. 
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FLT3-ITD is one of the most common genetic alterations in childhood AML and is 
associated with poor prognosis. Even recently, FLT3-ITD AML patients showed just a 
slight improvement in outcome notwithstanding the more intensive chemotherapy adopted 
in different international protocols
9,10,12
. A large number of studies have been published 
principally on adult AML
15
 with the aim of defining which biological characteristics may 
be considered in order to improve outcome of FLT3-ITD patients, but data are still 
contradictory.
12,15,16
 This study investigated for the first time the prognostic impact of the 
structural variability of the ITD mutation and of the FLT3-ITD AR in a large pediatric 
cohort on both cDNA and DNA. The ITD-AR measured on cDNA impacts on patient’s 
survival increasing the probability of treatment failure due to a lower rate of CR 
achievement. The expression of the mutation sustains a different sensitivity of the leukemic 
clone to therapy and the high-ITD-AR can be considered a reliable independent factor 
predictive of poor survival since diagnosis. Then, we considered that MRD assessment will 
be useful to track residual disease at early stage in order to create a molecular profile to 
personalize treatment and improve survival. The RQ-PCR based method to monitor MRD 
revealed that FLT3-ITD-positive patients since the end of the first induction course present 
a higher risk of relapse. MRD provide early additional prognostic information within this 
cohort of patients that can direct a subsequent different therapeutic management of 
patients. The predictive power of molecular MRD when measured before HSCT was not 
significant, probably due to the small sample size but suggest that MRD levels identify 
those patients with a higher risk of post-HSCT relapse. MRD can also at this stage be used 
for a more informed management of transplantation. Future trials will test whether these 
patients with positive MRD before HSCT can have a higher chance of success if treated 
with low intensive GVHD prophylaxis aimed at optimizing the donor graft-versus 
leukemia effect, or with novel approaches, such as those based on the use of CAR T cells 
during the conditioning regimen
43
. 
In an attempt to assess if the different clinical behavior within FLT3-ITD patients 
can have an evident biological basis, we interrogated the expression profile. We found that 
patients with high-ITD-AR at diagnosis were transcriptionally different from those that had 
low-ITD-AR, this finding supporting the concept that the expression levels of the mutation 
orchestrate diverse oncogenic pathways. Differentially expressed genes were found to be 
significantly connected with tri-methylation of H3K27. Also the expression profile of 
patients with a worse response to induction therapy was found to be different from that of 
the good responders, and genes regulated by histone acetylation were found to be 
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aberrantly expressed. Both analyses converged in sustaining that a high-AR or persistent 
expression of FLT3-ITD mutation exert an aberrant control principally of the epigenetic 
program that could be responsible of the worse prognosis. Moreover, we found both 
subunits of the AP-1 complex, JUN and FOSB, were over-expressed in the subgroup of 
high-ITD-AR patients, this finding sustaining their role in shaping the epigenome of FLT3-
ITD patients as recently demonstrated.
44
 Aberrant histone methylation and acetylation are 
considered crucial processes during tumorigenesis, and histone deacetylase inhibitors 
(HDACi) are promising epigenetic cancer drugs.
45,46
 Such drugs are currently under 
evaluation in combination with other chemotherapeutic agents for their antileukemic 
potential in FLT3-ITD adult leukemia showing a synergistic apoptotic induction with 
FLT3-ITD kinase-inhibitors,
45,46 
opening
 
for their further consideration also in pediatric 
selected subgroups of patients.  
In addition, we directed our attention toward CyclinA1 which was found 
overexpressed in FLT3-ITD patients when compared to the rest of AML. CyclinA1 has 
been documented to be leukemogenic in vitro and in vivo,
35,36,47–49
 and to be a biomarker 
for adults with AML.
44,50 
CyclinA1 has never been explored in pediatric leukemia field. 
Here, CyclinA1 presented its highest levels among the patients who either did not respond 
to induction or had higher ITD-AR, both features of worse prognosis. Then, we found the 
B-MYB transcription signature differentially expressed among higher ITD-AR patients, 
supporting that high levels of CyclinA1, in complex with CDK2, overactivates the B-MYB 
transcription factor and its oncogenic signature in this subgroup of FLT3ITD patients, 
contributing to their treatment failure.
38
  
In conclusion, we report the heterogeneity of FLT3-ITD AML patients documenting 
that evaluation of ITD-AR at diagnosis and molecular monitoring of MRD after the first 
induction course could be instrumental in stratifying patients in different risk groups, as 
well as to tailor different treatment within this pediatric AML subtype. We shed light on 
the role of FLT3-ITD mutation, revealing that patients present differences in epigenetic 
control, mostly in methylation and acetylation pathways, as well as in CyclinA1 expression, 
which may explain the variability in outcome among FLT3-ITD pediatric patients. These 
findings suggest the use of epigenetic drugs, combined with conventional strategies, to 
improve the outcome of pediatric FLT3-ITD patients with high ITD-AR and MRD levels.  
Finally, this study confirm the role of the molecular MRD approach as a strategy to 
be further enlarged to all molecular markers for a precise and sensitive track of the 
leukemia clone in order to adopt a personalized medicine, reduce relapse and increase 
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children survival. These results wish for future clinical collaborative pediatric trials which 
will focus on small well-defined and carefully-selected patient cohorts, taking into account 
the differences in mutation burden and in response to treatment, in order to define 
standardize protocols and cut-off to be used in routine laboratories.  
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SUPPLEMENTARY INFORMATION 
Supplementary methods. 
FLT3-ITD PCR and Allelic Ratio (ITD-AR) determination. FLT3-ITD screening 
was performed on cDNA of the 54 mutated patients by PCR at exon 14 using the 
Platinum® PCR SuperMix (Life Technologies) and the following forward (6FAM-
GCAATTTAGGTATGAAAGCCAGC) and reverse primers 
(CACCTGATCCTAGTACCTTCCC). Fragments were run on a 3500DX Genetic 
Analyzer and analyzed with the GeneScan® Analysis Software; samples showing a 
mutated profile were then analyzed to determine the ITD allelic ratio (AR). ITD-AR was 
determined normalizing the peak height of the ITD amplicon to the peak height of the 
wild-type amplicon. For a large series of patients (37/54), we also measured the ITD-AR 
on DNA using the same primers. We considered the AR-ITD >0.51 as the cutoff to 
discriminate patients with high presence of ITD compared to wild type allele as previously 
defined.
1
 The predictive role of the ITD-AR was then calculated on the 37 patients for 
whom both samples sources, namely cDNA and DNA, were available. 
FLT3-ITD and Cyclin A1 RQ-PCR. FLT3-ITD RQ-PCR was performed using a 
patient specific primer together with a common primer (TCCATAAGCTGTTGCGTTCA) 
and a common probe (Fam-TTTCCAAAAGCACCTGATCCTAGTACCT-Tamra). As 
housekeeping gene was used GUSB (F GAAAATATGTGGTTGGAGAGCTCATT, R 
CCGAGTGAAGATCCCCTTTTTA, probe Fam-
CCAGCACTCTCGTCGGTGACTGTTCA-Tamra). CyclinA1 was amplified with the 
following primer  TCAGTACCTTAGGGAAGCTGAAA  and 
CCAGTCCACCAGAATCGTG and normalized on GUSB expression (amplified with the 
abovementioned primer). 
Gene expression analysis. Bone marrow RNA from 85 patients with de novo AML 
at diagnosis were hybridized on the GeneChip® Human Transcriptome Array 2.0 
(Affymetrix), following RNA quality evaluation on an Agilent2100 Bioanalyzer (Agilent 
Technologies). Briefly, 100 ng of total RNA with integrity number (RIN) higher than 8 
were labeled and hybridized on the array  for 16 h at 45°C using a rotational oven, and 
washed according to Affymetrix standard protocols using a GC450 Fluidics Station. The 
Genechips were scanned with an Affymetrix 7G scanner and the CEL files generated were 
analyzed through Affymetrix Expression Console Software (version 1.3) which normalizes 
array signals using a robust multiarray averaging (RMA) algorithm. Normalized data were 
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analyzed using Transcriptome Analysis Console (TAC) 3.0 Software (Affymetrix). An 
unpaired t-test was applied to identify differentially expressed transcript genes between 
sample pairs and probes with P-values less than 0.01 and fold-change >2 were declared 
significant. Whenever possible, the transcript clusters were annotated using the RefSeq 
database. Microarray expression data are available in the U.S. National Center for 
Biotechnology Information Gene Expression Omnibus (GEO) database under accession 
number GSE74183. To visualize similarity of gene expression patterns, we applied 
hierarchical clustering and principal component analyses methods implemented in pca3d 
package of R 3.1.1 software (http://www.R-project.org). 
Gene functional enrichment analysis. We examined whether the differentially 
expressed genes are biologically meaningful via functional enrichment analysis using the 
integrative web-based software Enrichr.
2
 This tool enables the detection of significant 
enrichment for a set of genes in different databases: Gene Ontology (GO) Consortium 
database, Kyoto Encyclopedia of Genes and Genomes (KEGG) database, and Reactome 
database. We used the whole human genome as a reference set for enrichment analysis and 
applied a hypergeometric test with a significance level of p ≤0.05. Using Gene Set 
Enrichment Analysis (GSEA) algorithm with signal-to-noise metric and 1,000 
permutations of the genes, we compared the gene expression signatures of patients with 
FLT3-ITD mutation either dividing them in high vs low AR, and then good vs poor 
responders (where good responders are defined as patients in whom MRD reduction after 
induction is >2 logs, and poor responders are defined as those in whom MRD reduction 
after induction is <2 logs). Enrichment of specific genes/pathways were considered 
statistically significant for p-values <0.05 and FDR <0.25. 
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Supplementary Figures. 
 
Figure 1S. FLT3 region of internal tandem duplication in the 35 sequenced patients. FLT3-ITD mutation, 
occurred within exon 14 of the FLT3 gene for all patients analyzed except 6, in whom the duplication 
interested exon 14 and part of exon 15. 13 had a perfect duplication, while 22 had also an insertion of 3 to 15 
random nucleotides maintaining the frame. A common region internal to all the ITDs that covered from 
aminoacid 591 to 597 is defined. Legend: duplicated aminoacids are in green, inserted mutations are in light 
blue. Numbers on top represent the wild-type aminoacids from 571 to 617. Exon 14 is represented in yellow, 
while exon 15 is in bluette   
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Figure 2S.  Clinical outcome  for patients harboring FLT3-ITD mutation with allelic ratio (ITD/wild type) 
higher or lower than 0.51 executed for RNA or DNA. A) Cumulative Incidence of relapse (by AR on cDNA). 
B) Cumulative Incidence of relapse (by AR on DNA). Abbreviations: p = p value, N= number of patients, E 
= number of events, SE = standard error 
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Figure 3S. Clinical outcome for patients harboring FLT3-ITD mutation that had a minimal residual disease 
(MRD) reduction greater (>) or lower (<) than 2 logs after the second induction cycle (ICE). The Figure 
reports data for A) Event-Free Survival (EFS), B) Cumulative Incidence of relapse. Abbreviation: p = p 
value, N= number of patients, E = number of events, SE = standard error. 
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Figure 4S. Clinical outcome  for patients harboring FLT3-ITD mutation that reduced molecular disease 
(MRD) more  (>) or less  (<) than 3 logs before HSCT. In the figure are illustrated  data for A) Event Free 
Survival (p = 0.07) and B) Cumulative incidence of relapse (p = 0.09) . Abbreviation: p = p value, N= 
number of patients, E = number of events, SE = standard error. 
 
Figure 5S. Quantitative comparison of MRD estimates by MFC and PCR for 24 follow up samples: A) 
Pearson Correlation and B) Bland-Altman plot of the difference of PCR-MRD and FCM-MRD (Difference) 
against the mean of the PCR-MRD and FCM-MRD (Mean of differences) after logarithmic transformation. 
The lines indicate the estimated mean Difference (continuous line) and the upper and lower limits of 
agreement, mean Difference ± 1.96 SD (dotted lines). 
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ABSTRACT 
t(6;11)(q27;q23)MLL-AF6 is a rare translocation associated with poor outcome in 
childhood acute myeloid leukemia (AML). The described mechanism by which MLL-AF6, 
through constitutive self-association and in cooperation with DOT-1L, activates aberrant 
gene expression does not explain the biological differences existing between t(6;11)-
rearranged and other MLL-positive patients, nor their different clinical outcome. Here, we 
show that AF6 is expressed in the cytoplasm of healthy bone marrow cells, and controls 
RAS-GTP levels. By contrast, in MLL-AF6-rearranged cells, AF6 is found localized in the 
nucleus, leading to aberrant activation of RAS and of its downstream targets. Silencing 
MLL-AF6, we restored AF6 localization in the cytoplasm, this mediating significant 
reduction of RAS-GTP levels and of cell clonogenic potential. The rescue of RAS-GTP 
levels after MLL-AF6 and AF6 co-silencing, confirmed that MLL-AF6 oncoprotein 
potentiates the activity of the RAS pathway through retention of AF6 within the nucleus. 
Exposure of MLL-AF6-rearranged AML blasts to Tipifarnib, a RAS inhibitor, leads to cell 
autophagy and apoptosis, this supporting RAS targeting as a novel potential therapeutic 
strategy in patients carrying t(6;11). Altogether, these data point to a novel role of the 
MLL-AF6 chimera and show that its gene partner, AF6, is crucial in AML development. 
INTRODUCTION 
The mixed lineage leukemia (MLL) protein is a histone H3 lysine 4-specific 
methyltransferase, commonly associated with transcriptional activation
1
. MLL is essential 
for both embryonic development and normal hematopoiesis, mainly through transcriptional 
regulation of the homeobox (HOX) gene
2
. Chromosome translocations involving MLL 
locus are one of the major genetic lesions leading to acute leukemia. MLL translocations 
are detected in up to 80% of infant acute leukemia, and in approximately 10-15% of 
childhood acute myeloid leukemia (AML)
3,4
. Aberrant proteins resulting from 
translocations, duplications or amplifications of the MLL gene cause alteration of the 
differentiation program with severe effects on leukemogenesis
5,6
. To date, more than 60 
fusion partners of MLL have been described, which result in AML, acute lymphoid (ALL), 
and bi-phenotypic or chemotherapy-related leukemias
7,8
. The underlying mechanisms for 
MLL-mediated leukemogenesis have been extensively studied; however, they still remain 
elusive for many of the described translocations. MLL-rearranged AML is, in fact, a 
heterogeneous disease, which depends on the MLL partner gene for its biological and 
clinical features, such as gene expression and genomic imbalances
4
. Among diverse fusion 
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genes, the one that has been consistently associated with the worst outcome both in adult 
and pediatric AML is MLL-AF6
9
.  
The t(6;11)(q27;q23) translocation is not rare in childhood AML
3,4
, and has been 
demonstrated to impart a worse prognosis with respect to other forms of MLL-rearranged 
AML. AF6 is a cytoplasmic protein with two distinctive features: one single PDZ and two 
RAS-interacting (RA) domains. The PDZ domain drives AF6 to specialized sites on the 
membrane, where it can interact with many molecules
10–15
; RA domains are homologous to 
RA domains of RAS effectors
12,16,17
. Altogether, these characteristics enable AF6, either 
alone or when fused to MLL, to modulate multiple signal transduction pathways in vivo, 
especially those involving RAS, Notch and Wnt
16
. In the MLL-AF6 chimera, AF6 protein 
maintains its functional domains, both PDZ and RA, showing no homology, either for 
sequence or function, to the product of any other MLL partner gene
18,19
. 
To define the role of MLL-fusion genes, several researches were conducted mostly 
on MLL-AF9 and MLL-AF10 chimeras, revealing that a functional hallmark of MLL 
fusion-chimera is a block of hematopoietic differentiation
20–23
. The proposed tumorigenic 
mechanism of MLL-AF6 is based on the acquired aberrant transcriptional capability. In 
fact, the transcriptional activation of MLL is described to be dependent on MLL-AF6 
homodimerization mediated by AF6, which acts as a scaffold protein that permits the 
interaction with target genes
24. Furthermore, Amstrong’s group recently showed that MLL-
AF6 requires DOT1L histone-methyltransferase activity to maintain its gene-expression 
program, which is considered to be its main oncogenic force
25
. 
In this study, we demonstrate that MLL-AF6 affects AF6 localization, in order to 
aberrantly activate RAS and its downstream signaling to empower the tumorigenic 
potential of myeloid cells. In particular, we show that MLL-AF6 sequesters AF6 in the 
nucleus, leading to increased levels of RAS-GTP in the cytoplasm. Silencing of the 
chimera re-localized the AF6 protein back into the cytoplasm, this leading to reduction of 
both RAS levels and activity. These results imply that RAS may play a crucial oncogenic 
role in AML, prompting us to perform further experiments aimed at disrupting its function. 
Chemical inhibition of RAS signaling affected the proliferation of t(6;11)-rearranged cells 
to the same extent as that observed after silencing the chimera. Therefore we explored the 
effects of a new targeted treatment, namely a farnesyltransferase (FTase) inhibitor, 
Tipifarnib, and demonstrated its efficacy in primary cultures from patients with t(6;11)-
rearranged AML.  
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MATERIALS AND METHODS 
Cell lines, primary cell cultures and patient samples. MLL-AF6-rearranged ML2 
and SHI-1 cell lines, MLL-AF9-rearranged NOMO1 and THP1 cell lines (DSMZ), 
mononucleated cells obtained from whole bone marrow collected from pediatric healthy 
donors (HBM), and newly diagnosed t(6;11)MLL-AF6 and t(9;11)MLL-AF9-rearranged 
AML blasts were cultured in RPMI1640 (Invitrogen-Life Technologies, Monza, Italy) as 
previously described
26
. Diagnosis of leukemia was established according to standard 
criteria based on immunohistochemical, immunophenotyping, and cytogenetic studies, as 
detailed in the AIEOP-2001/02 AML treatment protocol
27
. In compliance with the Helsinki 
Declaration, informed consent was obtained from patients’ parents.  
Sequencing. Bone marrow samples of t(6;11) pediatric AML were analyzed for 
mutations affecting p53 (exon 6-exon 8); N- and K-RAS mutation where searched in 
hotspot region of exon one and two at codon G12, G13 and Q61 by Sanger sequencing.  
Immunofluorescence microscopy. Cytospins were incubated overnight at 4°C 
with 1:500 anti-AF6 (BD Biosciences, Milan, Italy) and anti-RAS (Cell Signaling 
Technology, Danvers, MA) antibodies. Slides were incubated with secondary antibodies 
conjugated to Alexa dyes (Invitrogen-Life Technologies). Cells were counterstained with 
4′,6-diamidino-2-phenylindole (DAPI; 1:10,000; Sigma-Aldrich, St. Louis, MO) to label 
nuclei. Staining was visualized by epifluorescence (video-confocal, Vico, Nikon, Tokyo, 
Japan). 
Western blot. Twenty μg of total proteins lysates, isolated as previously 
described
26
, were subjected to SDS-polyacrylamide gel electrophoresis (PAGE). 
Immunoblots were hybridized with anti-C-terminal portion of AF6 (BD Biosciences); anti-
β-actin, anti-c-RAF, anti-MEK1/2 (Sigma-Aldrich); anti-HDAC1 (Santa Cruz 
Biotechnology, Dallas, TX); anti-RAS, anti-phospho-c-RAF (Ser338), anti-phospho-
MEK1/2 (Ser217/221), anti total and phospho-ERK1/2 (Thr202/Tyr204), anti-LC3 (Novus 
Biologicals, Littelton, CO) and anti-p62 (Abnova, Taipei City, Taiwan). Enhanced 
chemiluminescence (ECL) western blotting detection reagents and films (GE Healthcare, 
Cleveland, OH) were used. Densitometric analyses for protein quantification were carried 
out using the ImageJ 1.38x software (http://rsbweb.nih.gov/ij/index.html). The value of 
each band was normalized to the value of either β-actin or total-RAS protein.  
Reverse phase protein arrays (RPPA). RPPA analysis was performed as 
described previously.
28,29
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RAS activation assay. A total of 20x10
6
 HBM or transiently silenced ML2 and 
SHI-1 cells were lysed and 500 μg of protein extract were used for the RAS Activation kit 
(ENZO Life Sciences, Lausen, Switzerland) according to the manufacturer’s instructions. 
Positive control samples were obtained by treating the lysates with GTPγS at a final 
concentration of 0.1 mM to activate endogenous RAS.  
Immunoprecipitation. ML2, SHI-1 and HBM cells were immunoprecipitated with 
8 μg of anti-RAS or anti-AF6 antibody, as previously described26. The immunoprecipitates 
were analyzed by SDS-PAGE.  
RNA interference. Two MLL-AF6-specific small interfering RNAs (siMAF6; 
QIAGEN GmbH, Hilden, Germany) were designed on the fusion breakpoint to selectively 
silence the chimera. To silence AF6, siAF6 (FlexiTube siRNA Hs_MLLT4; QIAGEN 
GmbH) was transfected into HBM cells. Double silencing with both siMLL-AF6 and 
siAF6 was also performed for rescue experiments. AllStars Neg Control siRNA (scRNA; 
QIAGEN GmbH) was used as control in each experiment. Cell transfections were 
performed using the Nucleofector systems (Amaxa Biosystems, Lonza Sales Ltd, Basel, 
Switzerland) according to the manufacturer’s instructions.  
RNA isolation and SYBR Green quantitative real-time reverse transcription-
PCR assays. Total RNA was extracted with Trizol reagent (Invitrogen-Life Technologies). 
One g of RNA was reverse-transcribed using the SuperScript II system (Invitrogen-Life 
Technologies) and random examers following the manufacturer’s instructions. Quantitative 
RT-PCR (RQ-PCR) reactions were performed in triplicate on an Applied Biosystems 7900 
HT (Applied Biosystems-Life Technologies). The comparative Ct method of relative 
quantification was applied to interpret the results
30
.  
Luciferase Assay. A mixture of pFOS WT-GL3 (Addgene, #11983
31
) plasmid, 
Renilla plasmid (REN), siMAF6 or siMAF6 and siAF6 were used to co-transfect cell lines, 
while a mixture of pFOS WT-GL3, REN, and scRNA was used as control. Real-time 
quantitative PCR (RQ-PCR) was used to monitor gene silencing. Protein lysates were 
analyzed for RAS activity by measuring LUC and REN levels using the Dual Luciferase 
Assay System (Promega Corporation, Madison, WI). LUC activity was normalized to REN 
activity.  
Soft agar colony assay. After MLL-AF6 silencing, a total of 2x10
3
 ML2 and SHI-
1 cells were seeded onto a minimum methylcellulose semisolid dish (StemCell 
Technologies, Vancouver, Canada) and incubated at 37°C. Fourteen days after 
transduction, colonies were counted by light microscopy after incorporation of MTT.   
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Apoptosis analysis. Transiently transfected cells were collected, double-stained 
with Annexin-V/propidium iodide (PI; Immunostep-Valter Occhiena, Turin, Italy) and 
analyzed using a Cytomics FC500 (Beckman Coulter, Brea, CA). Relative apoptosis was 
calculated and expressed as the percentage of Annexin-V-positive/PI-positive cells. Cell 
lines or cultures of primary AML blasts harboring either t(6;11) or t(9;11) were seeded at 
10
6 
cells per well and treated for 24h with a concentration of Tipifarnib ranging from 0.1 
μM to 10 μM.  
Microarray analysis. RNA was extracted from bone marrow of 11 MLL-AF6-
rearranged patients, as well as from a series of 11 HBM. RNA quality was assessed on an 
Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany). The GeneChip 
Human Genome U133 Plus 2.0 array was used and analyzed as previously described
32
. T-
test was used for supervised analysis between t(6;11)-rearranged patients and HBM 
samples (GSE 19577). To control for false discovery rate (FDR), multiplicity corrections 
were used; probes with adjusted p-values less than 0.01 were declared significant using 
Partek Genomic Suite Software. DAVID Functional Annotation Bioinformatics 
Microarray Analysis was used to identify molecular networks among differentially 
expressed genes. 
Reagents and treatments. ML2 and SHI-1 cell lines were treated with PD98059 
(40 M, Calbiochem, Merck group, Darmstadt, Germany), a MEK inhibitor. ML2, SHI-1, 
harboring the t(6;11), and NOMO- 1 and THP-1 cell lines harboring t(9;11), as well as 
primary AML cells from patients with the same two translocations were treated with 
Tipifarnib (0.1-100 M, Aurogene srl, Rome, Italy). MTT test was used to assess cell 
proliferation. 
Data analysis. Statistical analysis was performed using Prism 4.02 (Graph Pad 
Software, San Diego, CA). Experiments were performed in duplicate or triplicate, and 
results were presented as mean ± standard error of the mean (S.E.M.) of replicate 
experiments. Statistical significance was evaluated by the unpaired Student's t-test. 
Differences were considered to be statistically significant at p values <0.05 and were 
indicated with an asterisk. 
RESULTS 
MLL-AF6 modifies AF6 localization, maintaining high RAS-GTP levels. There 
are alternative AF6 isoforms with described specific subcellular localization. In particular, 
AF6 has been found ubiquitously expressed in different cell types, having a cytoplasmic 
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localization. A shorter splice variant of AF6 with nuclear localization was reported 
exclusively in cells of the central nervous system
33
. To define the distribution of AF6 in 
normal hematopoietic cells, HBM cells were immunostained with an AF6-specific 
antibody. In these cells, AF6 was expressed within the cytoplasm (Fig.1A). Western blot 
analysis confirmed its localization; in fact, only the cytoplasmic (Cyt) protein fraction 
showed AF6 expression. Furthermore, in HBM, AF6 was found to co-localize with RAS; 
these data were confirmed by co-immunoprecipitation experiments as previously described 
in other systems (Fig.1B)
14,16,31
. ML2 and SHI-1, two leukemia cell lines carrying the 
t(6;11)(q27;q23)MLL-AF6 translocation, were also investigated for AF6 localization. 
Immunofluorescence showed a nuclear punctate localization for AF6 in both t(6;11)-
rearranged cell lines. Nuclear subcellular position of AF6 protein was then confirmed by 
Western blot. Immunoprecipitation assay demonstrated no interaction between AF6 and 
RAS in t(6;11)-rearranged cell lines, due to the nuclear localization of AF6 (Fig.1C). We 
subsequently measured RAS activity in HBM and in leukemia cell lines by GST-pull down 
of the active form of RAS. ML2 and SHI-1 cells had an elevated amount of RAS in its 
active GTP-bound status, while the amount of active RAS was low in HBM cells, this 
supporting the hypothesis that AF6 may act as repressor of RAS activity in normal 
hematopoietic cells (Fig.1D).  
 
Figure 1. MLL-AF6 modifies AF6 localization from cytosol to nuclear. A) AF6 co-localizes with RAS 
(merged) in cytosol of healthy bone marrow (HBM) cells: (left) immunofluorescence of HBM primary cells 
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stained with DAPI and respective antibodies against AF6 and RAS (20X zoom). B) (up) Western blot 
analysis (WB) of AF6 and RAS expression in cytoplasmic (Cyt) and nuclear (Nu) cell extracts. (low) Co-
immunoprecipitation (IP) of AF6 and RAS in HBM cells. Total lysates (To) were used as positive controls; 
negative controls (-). C) (up) Nuclear localization of AF6 in ML2 and SHI-1 cell lines by 
immunofluorescence (AF6 red, nuclei stained with DAPI in blue, 20X zoom). WB of AF6 and RAS 
expression in total (To), cytoplasmic (Cyt) and nuclear (Nu) cell extracts; anti-HDAC1 and anti-ACTIN were 
used as endogenous controls for nuclear and cytoplasmic proteins, respectively. (low) Co-
immunoprecipitations (IP) between RAS and AF6 showed no interaction between the two proteins in neither 
of t(6;11) leukemic cell lines. D) Active RAS-GTP levels in ML2, SHI-1, and HBM cells; positive control +. 
Silencing of MLL-AF6 in t(6;11)-rearranged AML cell lines restores AF6 
localization in the cytoplasm and reduces RAS hyperactivation. Silencing of MLL-AF6 
in ML2 and SHI-1 decreased its mRNA expression as compared to cell lines transfected 
with a non-silencing scramble siRNA (scRNA). In particular, ML2 showed an average 
reduction of 46% and 38% at 24 and 48 hours, respectively, while SHI-1 showed an 
average reduction of 53% and 19% at the same time points (by RQ-PCR, data not shown). 
Chimera protein levels were decreased, as shown by Western blot experiments (Fig.2A). 
AF6 and RAS localization was investigated after silencing. We demonstrated that AF6 was 
in the cytoplasm in the MLL-AF6-silenced cell lines (Fig.2B) as well as in a primary 
sample of a t(6;11)-rearranged patient (Fig.2C), whereas it was retained in nuclear foci in 
scRNA-transfected cells. We also showed a restored co-localization of AF6 and RAS in 
the cytoplasm (Fig.2B and Fig.2C), as observed in HBM. We measured the active GTP-
bound status of RAS and found that it was decreased in cells silenced for MLL-AF6 
compared to scRNA (0.47 vs. 1, respectively; Fig. 2D), suggesting that the chimera 
maintained AF6 within the nucleus preventing its control over RAS activation.  
To confirm our hypothesis, we set up a luciferase assay system in which t(6;11)-
rearranged cell lines were co-transfected together with siRNA for MLL-AF6 and a 
luciferase reporter of RAS activity. Results showed that luciferase activity was reduced 
after MLL-AF6 silencing and AF6 re-localization in the cytoplasm, supporting RAS 
activity impairment (n=3, p=0.008, Fig. 2E) and the correlation between these events. We 
then confirmed that co-silencing both MLL-AF6 and AF6 increased the luciferase activity, 
because of RAS rescued expression (n=3, p=0.05, Fig. 2E). This phenomenon was also 
reinforced by measuring the main RAS target, ERK, which showed a decrease in 
phosphorylated ERK (p-ERK) form in MLL-AF6-silenced ML2, over the total ERK protein 
which remained at the same levels. By contrast, the ratio p-ERK/ERK increased again after 
MLL-AF6 and AF6 co-silencing (the ratio is represented in the histogram). In line with our 
hypothesis, the chimera silencing promoted the re-localization of AF6 into the cytoplasm, 
89 
 
thus restoring its control over RAS activity. In the same system, by reducing AF6 levels 
we rescued RAS activity. 
 
Figure 2. Silencing of MLL-AF6 in t(6;11)(q27;q23) rearranged cells restores AF6 in the cytoplasm. A) 
Western blot (WB) revealed a decreased levels of MLL-AF6 after silencing (siMLL-AF6) compared to 
negative controls (scRNA) in both, ML2 and SHI-1. Anti-ACTIN was used as endogenous control. B) 
siMLL-AF6 cells restored AF6 protein in the cytoplasm. Immunofluorescence shows co-localization of AF6 
(red) and RAS (green) in SHI-1 after MLL-AF6 silencing (merged signals yellow, nuclei blue, 60X zoom). In 
the negative control (scRNA), the punctuate pattern of AF6 nuclear localization is visible (red AF6, nuclei 
blue, 60X zoom). C) siMLL-AF6 cells restored AF6 protein in the cytoplasm. Immunofluorescence shows 
co-localization of AF6 (red) and RAS (green) in primary t(6;11)-AML after MLL-AF6 silencing (merged 
signals yellow, nuclei blue, 60X zoom). In the negative control (scRNA), the punctuate pattern of AF6 
nuclear localization is visible (red AF6, nuclei blue, 60X zoom). D) Active RAS-GTP levels in ML2 cell line 
silenced for the chimera showed a decreased activity of RAS (0.47) compared to scRNA..D) Luciferase 
(LUC) activity of ML2 transfected with a pFOS WT-GL3 plasmid and siMLL-AF6 show a reduction of LUC 
activity compared to scRNA. Introduction of both siRNA for MLL-AF6 and AF6 show a rescue of LUC 
activity in ML2. E) WB of P-ERK1/2 and total ERK in ML2 silenced for MLL-AF6 and in double silencing 
of MLL-AF6 and AF6 compared to scRNA. (right) Histogram represents the ratio between P-ERK and total 
ERK: a reduction of P-ERK is visble after MLL-AF6 silencing, and a rescue of P-ERK is documented when 
also AF6 was silenced.  
 
MLL-AF6 knockdown controls RAS-GTP levels influencing both RAS 
signaling pathway and cell proliferation.To demonstrate the relationship between MLL-
AF6 and the RAS pathway, we analyzed the expression of its main downstream targets. 
Figure 3A shows that, after MLL-AF6-silencing, expression of the phosphorylated active 
form of c-RAF, MEK1/2 and ERK1/2 is decreased in both ML2 and SHI-1. Densitometry 
was used to assess the extent of protein down-regulation; results are detailed in figure 3A. 
We confirmed the findings of Western blot analyses by using the sandwich-based enzyme-
linked immunosorbent assay (ELISA) technique, since we obtain a 21% reduction of 
phospho-ERK1/2 levels (p=0.02) in ML2 and SHI-1 cell lines after silencing of the 
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chimera, whereas other analyzed proteins which are not targets of RAS signaling, such as 
phospho-p53, phospho-AKT and phospho-JUN, were not affected by silencing (data not 
shown). Moreover, using an RPPA assay, we demonstrated that silencing of the chimera 
induces a reduction of p-ERK and p-MEK as well as an increase of the expression levels of 
proteins involved in apoptosis, such as the cleaved caspase 7 and PARP (Fig. 1S). We 
confirmed the oncogenic potential of the chimera also by measuring the clonogenic 
capacity after its silencing. A reduction of about 80% of colony number for ML2 and 55% 
for SHI-1 was found after silencing (Fig. 3B, n=2; p<0.05). Under these conditions, 
apoptosis was also increased compared with controls for both cell lines (ML2: 37.8% vs. 
51.9%, n=3; p<0.01, SHI-1: 12.8% vs. 16.0%, n=3; p<0.05).  
 
 
Figure 3. AF6 controls RAS-GTP levels and RAS downstream pathway. A) WB analyses of the 
RAF/MEK/ERK pathway after silencing of MLL-AF6 in ML2 and SHI-1 cell lines: a decreased level of 
phosphorylation for c-RAF, MEK1/2 and ERK1/2 is visible compared to negative controls (scRNA); anti-
ACTIN was used as control for total protein amount. B) (up) A decrease in colony formation (% with respect 
to scRNA) on semisolid medium, and (low) an increase in apoptosis (Annexin and PI positive cells) in ML2 
and SHI-1 cell lines after MLL-AF6 silencing (siMLL-AF6) compared to scRNA are observed (n = 3; p < 
0.05). C) Treatment of ML2 and SHI-1 cells with PD98059, 40 µM. WB analysis shows P-ERK1/2 reduction 
after treatment. Anti-ACTIN was used as positive control of protein amount. D) (left) An increased apoptosis 
and (right) a decreased percentage of colony formation is measured after treatment with PD98059 compared 
to negative controls treated with DMSO (n=2; p* < 0.05).  
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To ascertain the newly discovered role of RAS pathway activation in childhood 
AML cells carrying the t(6;11) translocation, we treated ML2 and SHI-1 cells with a 
chemical inhibitor of RAS signaling, PD980596. In both lines, we confirmed down-
regulation of pERK, the main downstream target of RAS (Fig.3C), as well as decreased 
clonogenicity up to 70% and 30% in ML2 and SHI-1 cell lines, respectively (n=3; p<0.05). 
Furthermore, PD980596 treatment alone increased apoptosis of t(6;11)-rearranged cell 
lines (ML2: 17.6% vs. 10.9% after DMSO treatment, n=3; p<0.05; SHI-1: 29.2% vs. 
12.1% of DMSO, n=3; p<0.05, Fig.3D). Taken together, these results demonstrate that 
inhibition of the RAS pathway, either by restoring localization of AF6 in the cytoplasm 
after chimera silencing or through the use of a chemical compound, concurred to blunt 
proliferation of MLL-AF6-rearranged cells. To further confirm the role of AF6 in 
controlling RAS activity in hematopoietic cells, we demonstrated increased 
phosphorylation of RAF/MEK/ERK proteins after AF6 silencing in HBM (30% reduction 
as determined by RQ-PCR, n=2; P<0.05; Fig. 1S), as previously described in other 
systems
34
. 
Gene expression profile of t(6;11)-rearranged pediatric patients supports the 
transcriptional activity of MLL-AF6 on HOXA genes and RAS pathway. Gene 
expression analysis using Human Genome U133 Plus 2.0 was performed on samples of 11 
AML t(6;11)-rearranged patients and of 11 HBM. Supervised analysis between these two 
groups identified 2,463 differently expressed probe-sets (1,747 genes, FDR <0.01). Among 
the differentially expressed genes, we found genes typically involved in MLL-rearranged 
leukemia, such as genes belonging to the MEIS1 and HOXA families (Fig.4A). With 
differentially expressed genes, we performed pathway analysis using the DAVID software, 
finding that the MAPK pathway and genes related to apoptosis were the most important 
deregulated pathways in t(6;11)-rearranged cells. Remarkably, in samples with t(6;11) 
rearrangement, we noted the down-regulation of a gene, RASA2, which encodes for a RAS-
GAP known to negatively regulate RAS activity, as shown in the box-plot (Fig. 4B, 
p<0.001), and confirmed by RQ-PCR (Fig. 4C, p<0.01). These results support the 
existence of an independent mechanism that enhances RAS activity in this type of 
leukemia, bringing to light that the RAS pathway sustains the leukemogenic properties of 
MLL-AF6-rearranged leukemia. Further supporting this finding, RASA2 expression is 
confirmed  to be downregulated in t(6;11)-rearranged patients as compared with MLL-
other leukemia (Fig. 4D, p=0.06 and p=0.05). 
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Figure 4. Hoxa genes and RASA2 are differentially expressed between t(6;11) patients and HBM cells. A) 
Hierarchical clustering analysis of 11 patient with t(6;11) (blue) and 11 healthy bone marrow (orange). B) 
Box-plot of RASA2 probe sets in t(6;11)-patients (white) vs. HBM (grey) samples generated using Partek 
Genomic Suite Software. Expression values are indicated in the boxes as the median of each group. Y-axis 
probe set expression values in log2 scale. C) Histogram confirmed the decreased mRNA levels of RASA2 by 
RQPCR (ΔΔCt method) in 11 MLL-AF6 rearranged patients. Results are calibrated to the 11 HBM (RQ=1). 
D) Box-plot of RASA2 probe sets in t(6;11)-patients vs. MLL-other leukemic samples generated using Partek 
Genomic Suite Software. Expression values are indicated in the boxes as the median of each group. Y-axis 
probe set expression values in log2 scale. 
Tipifarnib promotes cell death of t(6;11)-translocated blasts. Since the 
prognosis of leukemia patients harboring t(6;11) is worse than that of patients with other 
MLL rearrangements
4
, we speculated that our findings about the role of the RAS in this 
subtype of leukemia might lead to novel therapeutic opportunity by using tipifarnib. 
Tipifarnib is a drug not currently used in treatment of pediatric AML, and currently 
adopted in clinical trials for different diseases
35–38
 for its ability to block the 
farnesyltransferase enzyme in order to inhibitits targets, among which there is Ras
39,40
. We 
treated t(6;11)-translocated cell lines, ML2 and SHI-1, as well as cell lines with different 
rearrangements of MLL, i.e. THP1 and NOMO1, both MLL-AF9 translocated, comparing 
increasing concentrations of different cytotoxic drugs currently employed for AML 
treatment, such as doxorubicin (Doxo), cytarabine (Ara-C), etoposide (VP16) with 
Tipifarnib. We observed that increasing concentrations of Doxo, Ara-C, and VP16 were 
able to reduce cell proliferation in all cell lines examined, and that ML2 were highly 
responsive to Tipifarnib, whereas SHI-1 and the two other t(9;11)-rearranged cell lines 
were not (Fig.5A).  
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Figure 5. Tipifarnib treatment provoked RAS inhibition and induced apoptosis of t(6;11)-rearranged cell 
line. A) MLL-rearranged cell lines treated with increasing concentrations of chemotherapics (Doxo, Ara-C or 
VP16; 0.01 -10 µM) showed a similar reduction in proliferation, while Tipifarnib (0.1 – 100 µM) was 
specifically reducing ML2 cell proliferation. B) WB analysis showed P-ERK1/2 reduced levels during 
increasingly Tipifarnib treatment in ML2. (C) Histogram represented the ratio between P-ERK and total ERK 
in ML2: a reduction of P-ERK was visible after Tipifarnib treatment. (D) WB analysis showed BIM and 
PARP cleavage increased after Tipifarnib treatment in ML2.  (E) WB analysis showed mTOR and p70S6K 
phosphorylated and total protein after Tipifarnib treatment in ML2 and THP-1. 
This different behavior between the two t(6;11)-rearranged cell lines, ML2 and 
SHI-1, has been already investigated by Chen et al., and found to be dependent on the 
presence of TP53 mutations, and associated with the documented greater multidrug 
resistance of this cell line
41
. We performed a western blot to confirm the RAS involvement 
observing that its pathway, in particular P-ERK1/2, resulted to be decreased at 16h post 
treatment with 1µM tipifarnib (Fig.5B). We confirmed the downregulation of P-ERK1/2 
by observing the upregulation of BIM
39
, and the apoptosis induction by PARP cleavage 
(Figure 5C and figure 5D). To check for off targets effects we analyzed the phosphoryation 
of mTOR and of the p70S6K, denoting a decrease in the phosphorylated as well as in both 
total proteins (Fig. 5E).  
Consistently with our hypothesis moreover we cannot detect a perturbation of the 
RAS pathway in Tipifarnib treated THP-1 cells. In view of these findings, we decided to 
treat with Tipifarnib cultures of primary AML cells obtained from patients with or without 
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the t(6;11) translocation. Tipifarnib increased cell mortality at 24h of treatment in cultured 
blasts of MLL-AF6-rearranged patients in comparison to cultures from patients with other 
aberrancies (Fig. 6A, n=2, p<0.05). Analyzing Tipifarnib effects, we showed that low 
concentrations of Tipifarnib (0.1 and 1 M) increased autophagy, as shown by LC3 and 
p62 expression; by contrast, this drug at concentrations higher than 10 M promotes 
apoptosis, as seen by PARP cleavage (Fig. 6B).  
 
Figure 6. Tipifarnib treatment provoked RAS inhibition and induces apoptosis of t(6;11)-rearranged primary 
cells. A) t(6;11) primary cell cultures treated with increasing concentration of Tipifarnib showed an 
accentuated induction of apoptosis (% Annexin V / PI positive cells) especially with increasing drug 
concentrations with respect to primary AML cultures with different MLL-translocation. B) (left) WB analysis 
showed P-ERK1/2 reduced levels during increasingly Tipifarnib treatment. LC3 and p62 documented 
autophagy induction at low Tipifarnib doses, while PARP cleavage confirmed apoptosis when higher doses 
of Tipifarnib was used. Anti-ACTIN was used as positive control for protein amount. (right) Histogram 
represented the ratio between P-ERK and total ERK: a reduction of P-ERK was visible after Tipifarnib 
treatment at any concentration.  
These results are consistent with previous reports demonstrating that RAS-induced 
tumorigenesis both in vitro and in vivo is always mediated by autophagy
42
. ERK 
phosphorylation was shown to be inhibited at every concentrations of Tipifarnib (Fig. 6B), 
confirming the targeting of the RAS pathway.  
Furthermore, we ruled out that RAS hyperactivation is dependent on gene 
mutations, since none of the 11 t(6;11)-rearranged patients had known mutations in hotspot 
region of N-RAS,K-RAS nor TP53, as expected in pediatric AML
43,44
.  
DISCUSSION 
The MLL-AF6 fusion transcript has been found in a significant proportion of 
children with AML, and is associated with the worst prognosis among all variants of MLL-
positive leukemia
2,4,6
. MLL partner genes are broadly classified into two distinct groups 
based on their structural characteristics and cellular localization: gene codifying for the 
nuclear partner proteins with features of putative transcriptional regulators, and genes 
codifying for cytoplasmic partners, associated with intracellular signaling
24
. AF6 protein is 
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the most frequent cytoplasmic partner in AML and has been previously found to ultimately 
orchestrate the aberrant transcription of MLL target genes as described by Cleary’s and 
Amstrong’s groups24,25.  
In this study, we identified a novel role for MLL-AF6 fusion protein in pediatric 
AML. We showed that AF6 and RAS co-localize and interact in the cytoplasm of healthy 
hematopoietic cells, while in t(6;11)-rearranged leukemia cells the two proteins have 
different localization, and hence the inhibitory effect of AF6 over RAS activation is lost. 
Liedtke et al. showed that AF6 exerts its function primarily as a scaffold protein for 
dimerization and activation of the transcriptional activity of MLL-AF6
24
. These authors 
demonstrated the ability of the chimera to homodimerize and activate its oncogenic 
potential trough the AF6
RA1
 domain which is capable of mediating self-association in vitro 
and is responsible of the self-association in the context of the MLL-AF6 fusion protein. 
Being documented the ability of RA1 to self-associate, we infer that AF6 can also 
heterodimerize with MLL-AF6, leading to a previously unrecognized and parallel function 
of this chimera, able to delocalize the wild-type AF6 to the nucleus, this enhancing the 
activation of RAS and its downstream pathway
24
. Here, we showed that AF6 shuttling 
from cytoplasm to nucleus determines the level of the RAS-GTP active form, contributing 
to the tumorigenic effect exerted by MLL-AF6 as a transcription factor. 
Gene expression analysis, in fact, revealed that primary blasts of MLL-AF6-
rearranged patients showed a gene expression profile typical of patients with other MLL-
associated rearrangements, in which HOXA cluster is mainly overexpressed
24
. However, 
we revealed that the MAPK pathway, acting downstream of RAS activation, is altered and 
that, among differentially expressed genes, RASA2, a known RAS inhibitor, is strongly 
down-regulated in t(6;11)-rearranged cells, supporting the aberrant activation of RAS 
signaling. The hypothesis that RAS levels depend mainly on AF6 expression in 
hematopoietic cells has been here for the first time addressed and confirmed by rescue 
experiments. In t(6;11)-positive AML, AF6 is found within the nucleus, and after silencing 
of both MLL-AF6 and AF6, an evident increase of RAS activity was documented, with the 
concomitant rescue also of phospho–ERK levels when compared to silencing of MLL-AF6 
alone.  
Several studies previously demonstrated that uncontrolled RAS activation is one of 
the most common genetic alterations associated with development of several human 
cancers, including adult MLL-rearranged leukemias
45–48
. This uncontrolled RAS activation 
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is mainly due to known somatic activating mutations
49,50
, or to the constitutive activation 
of several receptor tyrosine kinases, such as CSF-1 and FLT3, or derives from the loss of 
function of tumor
 
suppressor genes, such as NF1 and PTPN11
51
. Even though the RAS 
pathway is over-activated in MLL-AF6-positive pediatric patients, in our cohort we never 
found mutations in the RAS gene, confirming our hypothesis of an active role of the 
chimera MLL-AF6 as the driving force of the observed aberrant RAS pathway activation.  
Taken together, these results should encourage further studies aimed at evaluating 
novel treatment modalities in the t(6;11)(q27;q23) subgroup of childhood AML, 
considering that this subgroup still carries a dismal prognosis
4
. To this purpose, we 
investigated the effect of the FTase inhibitor Tipifarnib
52
, which hampers the attachment of 
the farnesyl moiety to the RAS protein, thereby repressing its activation. This drug is 
currently under evaluation in hematological diseases with high rates of RAS mutation and 
activation
35–38,53,54
. A phase-1 study showed that pediatric patients with resistant or 
refractory AML well tolerated Tipifarnib, although a poor clinical response was observed, 
partially due to the fact that RAS hyperactivation is not demonstrable in all AML variants. 
Support to the rationale of using Tipifarnib is provided by the observation that apoptosis 
after drug exposure was enhanced in primary blasts carrying t(6;11), while blasts carrying 
other MLL rearrangement of childhood AML never showed relevant sensitivity to this 
drug. Notably, leukemia cells were sensitive to high concentrations of the drug, whereas 
low concentrations failed to induce apoptosis caused by a parallel activation of the 
autophagy process. This finding has been discussed in several works showing that many 
cancer cells with aberrant RAS activation have a high basal autophagy, and some depend 
on autophagy for normal growth
55
. Autophagy is a dynamic process that prolongs survival 
for a short time under stress conditions
56
; therefore, blocking autophagy with conventional 
inhibitors
37
, together with the use of Tipifarnib, could be considered for t(6;11)-rearranged 
patients.  
Since most patients with t(6;11) succumb within 1 year from diagnosis due to resistance to 
conventional cytotoxic therapy, RAS targeting promises to be a new valuable option for 
this subset of childhood AML. 
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SUPPLEMENTARY INFORMATION 
Supplementary figures 
 
Figure 1S. Elisa assay in ML2 and SHI-1 after MLL-AF6 silencing  denoted decreased expression of proteins 
involved in RAS signaling pathway and increased levels of cleaved caspase 7 and PARP in ML2 and SHI-1 
after MLL-AF6 silencing.  
 
 
Figure 2S. AF6 silencing in primary culture of healthy bone marrow enhanced RAS pathway activation. 
Western blot analyses on HBM silenced for AF6 (siAF6) showed increasing levels of P-c-RAF, P-MEK1/2 
and P-ERK1/2 proteins with respect to negative controls (scRNA); anti-ACTIN was used as positive control 
of protein amount. Values depicted in the figure represent densitometry of the bands obtained with ImageJ 
software. 
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ABSTRACT 
Oncogenic fusion proteins are often key players in childhood acute myeloid 
leukemia (AML), and Nucleoporin 98 (NUP98) is described to translocate at least with 29 
different partner genes. However, no comprehensive studies have investigated the 
incidence or the prognostic relevance of most of the NUP98-fusions, nor analogy and 
dissimilarity in their clinic and leukemogenic role. Here, we screened the pediatric Italian 
AML cohort (N=482) for 12 NUP98 partners finding 22 positive patients (4.6%) harboring 
NSD1, PHF23, JARID1A, DDX10, HOXD13, LEDGF characterized by a dismal 8 years 
event free survival (27% versus 56.2% of other AML). Gene expression profiling (GEP) 
highlighted that this newly identified AML entity present a significant different coding as 
well as a non coding signature compared to others genetic subtypes of AML (CBF, MLL, 
FLT3-ITD). Each partner gene was revealed unique for GEP and outcome. NUP98-NSD1 
was the most represented fusion, with the worst outcome (16.6%) and the lowest HOXA 
and B cluster genes expression among all NUP98-AML, supporting alternative co-
operating processes to cause this aggressive type of leukemia. We underpinned in NSD1-
NUP98 rearranged primary cells the involvement of both, the cAMP/CREB signaling and 
chromosome instability (CIN), being the main networks enriched by gene ontology. An 
enhanced CIN and a pivotal role of the transcription factor CREB in controlling NUP98-
chimeras expression were demonstrated. These findings declare NUP98 rearrangements a 
not rare high risk AML category defined by diverse leukemogenic processes occurring for 
each oncogenic protein. We support CREB inhibitors clinical investigation for a more 
targeted NUP98-AML treatment. 
INTRODUCTION 
Chromosomal rearrangements involving the human NUP98 (Nucleoporin 98kDa) 
gene have been recently found associated with a wide range of hematological disorders, 
including leukemia
1–3
. NUP98, like MLL, is a promiscuous gene, reported to mate with 
more than 29 distinct partners, forming fusion oncoproteins that concur to acute myeloid 
leukemia (AML) development
1
, thus NUP98 rises as a key player in this cancer. Among 
the different NUP98 rearrangements, NUP98-NSD1 and JARID1A were the only fusions 
described in childhood AML presenting an aggressive leukemia and disappointing 
treatment outcome
2,3
.  
Of note, all fusions have the same structure: the amino terminal portion of NUP98, 
containing the Gly-Leu-Phe-Gly (GLFG) residues, interacts with histone-modifying 
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enzymes such as CBP-p300, and joins in frame the C-terminal of different proteins. Most 
of the NUP98 known partner genes harbor the homeodomain (HD), several others without 
HD can directly or indirectly activate gene transcription
1
. Indeed, NUP98-translocations 
have been associated with the deregulation of HOXA and HOXB cluster genes, both 
important for normal hematopoiesis.
4
 Moreover, the abnormal expression of the HOXA 
genes has been demonstrated to impair normal cell differentiations and enhances self 
renewal of hematopoietic stem cells, as reported for the leukemic transformation induced 
by MLL rearrangements
4–6
. This differentiation defects confer to the NUP98-translocations 
characteristics of type II aberrations and leads in mice, after a long latency, to an impaired 
myelopoyesis with the development of a hematopoietic diseases
7–9
. Cooperating type I 
molecular aberrations, such as FLT3-ITD or RAS mutations, concur to disease progression 
from MDS to leukemia
7,10
. In pediatric AML, indeed, it has been reported a frequent 
association between FLT3-ITD and NUP98-NSD1
2,11
. 
Despite recent reports, no comprehensive studies have been undertaken to 
investigate the incidence or the prognostic relevance of NUP98-fusions in childhood AML 
or to uncover similarities and differences in their neoplastic mechanism. In addition, it is 
not yet clear whether NUP98-partner gene reflects diversity in initial fusion events, cell 
type or mechanism of action. 
Here, to increase the clinical and biological understanding of NUP98-fusions, we report the 
results of an exhaustive study in a pediatric AML cohort (N=482) enrolled in a single 
clinical protocol (AIEOP 2002/01)
12
. Moreover, we took advantage of a genome-wide 
technology (HTA 2.0, Affymetrix) in order to bring further insight into the biology of this 
NUP98-translocated leukemia, focusing on its characterization either by a RNA coding and 
non coding expression profile. Results firstly elucidated the main altered oncogenic 
transcriptional programs induced by the presence of each NUP98-fusion going beyond the 
already reported HOX overexpression, and shedding light on a possible route to treatment 
of these patients. 
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METHODS  
Patients. Bone marrow (BM) sample from patients with de novo AML at diagnosis 
(N= 482), aged from 0 to 18 years, enrolled in the AIEOP LAM 2001-2002 protocol were 
included in this study
12
. Patients with granulocytic sarcoma, secondary AML, secondary 
myelodysplastic syndrome (MDS), or Down syndrome or patients with acute 
promyelocytic leukemia were excluded from the present analysis. In agreement with the 
Declaration of Helsinki, written informed consent was obtained from their parents. The 
initial diagnosis of AML according to the FAB classification, immunophenotype and 
molecular characterization was centrally reviewed in the Laboratory of Pediatric 
Hematology at the University Hospital in Padova. 172 of the 482 patients were found 
negative for the recurrent genetic abnormalities involving MLL, CBF, ,FLT3-ITD and some 
other rare aberrancies included in the protocol screening panel for risk stratification
11–13
. 
The molecularly negative and the 42 FLT3-ITD rearranged were screened for 12 NUP98 
fusions. 
RNA isolation, polymerase chain reaction (PCR) analysis and Real Time-PCR. 
Total RNA was isolated using Trizol (Invitrogen-Life Technologies, Monza, Italy). One 
microgram of RNA was reverse-transcribed into cDNA using SuperScript II (Invitrogen) 
according to the manufacturer’s instructions. For molecular screening multiplex RT-PCR 
were performed using Platinum® PCR SuperMix (Invitrogen-Life Technologies, Monza, 
Italy). Sanger sequencing was executed to all positive cases to characterize fusion 
breakpoints and to asses genes mutations (c-KIT, IHD1, NPM1, N and K RAS). Briefly, 
3.1 BigDye Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) was 
used and reaction was analyzed on the 3500DX Genetic Analyzer (Applied Biosystems). 
Expression of mRNA were measured by Real Time PCR (RQ-PCR) on an ABI 7900HD 
platform (Applied Biosystems) using the Syber Green PCR master mix (Applied 
Biosystems) and normalized on GUSB using the 2^-DDCt method
14
. See Supplementary 
Methods for primer sequences. 
Gene expression analysis. RNA from bone marrow of patients with de novo AML 
at diagnosis (N=85) were hybridized on the GeneChip® Human Transcriptome Array 2.0 
(Affymetrix, Santa Clara, CA)) containing >6.0 million probes covering coding and non  
coding transcripts. The analysis was performed for 19 patients harboring NUP98-
translocations (NUP98-t), 20 patients with core-binding factor (CBF) aberrations (RUNX1-
RUNX1T1 and CBFB-MHY11), 7 with MLL-rearrangements, 7 with t(6;9)(p23;q34)DEK-
NUP214, 8 carrying FLT3-ITD mutation and 24 patients negative for known recurrent 
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genetic abnormalities screened. RNA quality was assessed on an Agilent2100 Bioanalyzer 
(Agilent Technologies, Waldbronn, Germany). Details are described in Supplementary 
Methods. Microarray expression data are available in the U.S. National Center for 
Biotechnology Information Gene Expression Omnibus (GEO) database under accession 
number GSEXXXX.  
Plasmid construction. EGFP-N1-ΔGFP-CREB plasmid was obtained as 
previously described
14
. Reporter construct for the wild type human NUP98 promoter 
containing the CREB binding sites (CRE) was PCR amplified from genomic DNA and 
cloned into the pXP2 promoter-less vector (pXP2-NUP98prom)
15
.  
Cell culture, transfection and treatment. Leukemia cell lines (HL60, U937; 
DSMZ) were cultured in RPMI1640 (Invitrogen-Life Technologies, Monza, Italy) 
supplemented with 10% fetal bovine serum (FBS; Invitrogen-Life Technologies, Monza, 
Italy) while human embryonic kidney cells (HEK293T) were cultured in DMEM 
(Invitrogen-Life Technologies, Monza, Italy) with 10% FBS as previously described
16,17
. 
Newly diagnosed t(5;11)NUP98-NSD1 rearranged AML blasts and ex vivo expanded 
NUP98-NSD1 cells were cultured in RPMI1640 supplemented with 10% FBS and 
cytokines rhIL-3 (20ng/mL), rhIL-6 (20ng/mL), rhSCF (50ng/mL), rhTPO (50ng/mL) and 
rhFLT-3 Ligand (50ng/mL). HEK293T transfections were carried out by CaPO4 
precipitation either using 1.0–4.0μg of expression construct pEGFP-N1-ΔGFP-CREB or 
negative control (pEGFP -N1) per 6cm dish or to selectively silence CREB, a 400pmol 
mix of two small interfering RNAs (QIAGEN GmbH, Hilden, Germany) previously used 
by Pigazzi et al
14
 and a all Stars Neg Control siRNA (QIAGEN GmbH, Hilden, Germany) 
used as control. Primary AML cells from patients with NUP98-t and healthy bone marrow 
(HBM) were transfected using the Nucleofector system (Amaxa Biosystems, Lonza Sales 
Ltd., Basel, Switzerland) according to the manufacturer’s instructions.) and CIN was 
evaluated by  nocodazole (300nM) and aphidicolin (0.5μM) (Sigma-Aldrich, St. Louis, 
MO) treatment for 24 hours.  
Cytogenetic and molecular analysis. Chromosomes analysis was performed was 
performed on metaphases on bone marrow cell (BM), using standard laboratory 
procedures. The karyotypes were reported according to the International System for 
Human Cytogenetic Nomenclature (ISCN 2013)
18
. The probe used for Fluorescence in situ 
hybridization (FISH) was a NUP98 Break Apart (BA) Probe Set dual color probe locus 
specific for 11p15 (Empire Genomics LLC).  
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Luciferase assay. HEK293T were transfected with a Renilla plasmid (REN), a 
Luciferase reporter containing either the wild type NUP98 promoter sequence (pXP2-
NUP98prom), or a mutated at CRE sequences of NUP98-promoter (pXP2-NUP98prom 
CREB CRE mut) or with the empty vector as internal control. Luciferase activity was 
determined by Dual-Luciferase® Reporter (DLR™) Assay System following Promega 
manufacturer's instructions.  
Chromatin immunoprecipitation. HL60 and U937 cell lines were processed for 
chromatin immunoprecipitation assay (Millipore, Darmstadt, Germany) as previously 
described
19
. Briefly, the immunoprecipitation was performed overnight at 4°C with 
rotation using two independent CREB antibodies (Sigma-Aldrich, St. Louis, MO 
/Millipore, Darmstadt, Germany ) and Immunoglobulin (Ig), as negative controls. Input 
DNA of HL60 cell line was used as positive control. DNA was recovered and amplified by 
PCR with selected primers (see tables of primer for sequences).  
Immunoblotting analysis. Total proteins lysates (20μg) were isolated as 
previously described
16
 and were subjected to sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis. Western blot were hybridized with anti-β-ACTIN, anti-HDAC, anti-
PARP, anti-NUP98 L205, anti-ϒH2AX (Ser139), anti-H2AX, anti-PP2A B55 (Cell 
Signaling Technology, Danvers, MA), anti-CREB (Sigma-Aldrich, St. Louis, MO 
/Millipore, Darmstadt, Germany ), anti-BUB1 (Abnova, Taipei City, Taiwan), anti-
MAD2L1 (Genetex, Irvine, CA), anti-CYCLIN B (BD Transduction Laboratories); the 
horseradish peroxidase–conjugated secondary antibody was either anti-goat, rabbit or 
mouse (Millipore, Darmstadt, Germany ). 
Data evaluation and statistical analyses. Probability of survival was established 
using Kaplan-Meier method and compared between groups through the log-rank test. EFS 
was calculated from date of diagnosis to last follow-up or first event (failure to achieve 
CR, relapse, second malignancy, or death due to any cause, whichever occurred first). 
Statistical comparisons between the study groups were also made. Pearson chi-square 
statistic was used to test for differences in the distribution of categorical variables. 
Statistical analyses for microRNA level were performed using the Mann-Whitney unpaired 
two-tailed t test. A p-value of p-value<0.05 was considered statistically significant. 
RESULTS 
Identification of Nup98 fusion genes. In order to evaluate the incidence of 12 
different NUP98-fusions, previously described implicated in AML or in other myeloid 
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disorders
1
, a large cohort of pediatric de novo AML enrolled in the AIEOP AML-2002/01 
protocol
12
 was screened by RT-PCR for NUP98 rearranged with NSD1, HOXC11, PHF23, 
HOXA9, JARID1A, HOXD13, LEDGF, DDX10, HHEX, ADD3, NSD3 and LOC348801. 
Altogether NUP98-fusion transcripts were detected in 22 cases with a frequency of 4.6% in 
the total AIEOP cohort (Fig.1A, Tab.1A). t(5;11)(q35;p15.5)NUP98-NSD1 was the 
translocation majorly detected (12 patients), followed by t(11;17)(p15.5;p13)NUP98-
PHF23 in 4 diagnosis, and t(11;21)(p12;p13)NUP98-JARID1A in 3 children; while 
t(2;11)(q31;p15)NUP98-HOXD13, t(9;11)(p22;p15.5)NUP98-LEDGF and 
inv(11)(p15q22)NUP98-DDX10 were found in just one case each. Specifically, 16 out of 
22 positive cases were identified among the 172 AML patients (9.3%) previously found 
negative for known recurrent genetic abnormalities involving CBF, MLL and FLT3 genes 
(Tab.1B). These NUP98-rearranged patients were found similar at diagnosis for sex 
distribution, median age and white blood cell count, and FAB to the rest of molecularly 
negative patients (Tab.1B), however all NUP98-JARID1A patients presented exclusively a 
M7 morphology confirming previously reported data
3
. Interestingly, 56% of NUP98-
rearranged patients presented a complex karyotype, defined with 3 or more structural or 
numerical chromosome aberrations, compared to 11% of the negative cohort (p-
value<0.0001, Tab.1B).  
 
Table 1. Clinical and molecular characteristics of NUP98-traslocated patients. Individual characteristics of 
NUP98-translocated AML patients (N=22). Abbreviations: Y, years at diagnosis; M, male;  F, female; WBC, 
white blood cell count; FAB= French–American–British classification. 
MARKER AGE, Y SEX
WBC count
(x10^6/L)
FAB Karyotype Mutations
NUP98-LEDGF 5 F 200000 M2 normal none
NUP98-NSD1 13 M 404000 M2 normal FLT3/ITD
NUP98-NSD1 15 F 327000 M5 normal FLT3/ITD
NUP98-NSD1 2 F 21440 M5 complex none
NUP98-NSD1 10 M 78000 M2 complex FLT3/ITD
NUP98-NSD1 8 F 17900 M2 normal none
NUP98-NSD1 6 M 202000 M5 normal FLT3/ITD
NUP98-NSD1 15 M 350000 M1 complex none
NUP98-NSD1 2 M 4100 M2 normal NPM1
NUP98-NSD1 2 F 286 M4 normal FLT3/ITD
NUP98-NSD1 2 M 83070 M2 normal none
NUP98-NSD1 9 F 218580 M5 complex FLT3/ITD
NUP98-NSD1 15 F 62800 M1 complex none
NUP98-HOXD13 1 M 24530 M1 complex none
NUP98-JARID1A 2 F 5830 M7 complex none
NUP98-JARID1A 2 F 28400 M7 complex none
NUP98-JARID1A 0 M 188000 M7 normal none
NUP98-PHF23 9 M 6950 M4 normal none
NUP98-PHF23 6 M 1850 M5 normal none
NUP98-PHF23 2 M 187900 M1 normal none
NUP98-PHF23 9 M 1220 M0 normal none
NUP98-DDX10 11 M 29700 M5 complex none
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Figure 1. NUP98-translocations are frequent events in pediatric AML. A) Pie charts showing the percentage 
of different type-II aberrations and of different NUP98-fusions in the pediatric Italian AML cohort (N=482, 
AML2002/01). B) Probability of event-free survival (EFS) in children with NUP98-translocations versus 
AML patients negative for recurrent molecular aberrations (NEG in the graph); C) or versus the entire Italian 
AML cohort enrolled; D) Cumulative incidence of relapse (CIR) in children harboring NUP98-
rearrangements and in the rest of the Italian AML cohort. Abbreviations: N, number of cases. 
Considering the clinical impact, we revealed that the NUP98 positive patients had a 
significantly dismal event free survival (N=16, EFS at 8 years=25%) compared to the rest 
of molecularly negative patients (N=156, EFS=49.6%; p-value<0.05, Fig.1B). Indeed, 
despite the high complete remission rate of NUP98-translocated (NUP98-t) patients (75%) 
similar to the negative cases (83.9%), 9 out of 16 NUP98 cases (56.0%) incurred in a 
relapse versus just the 25% in the juxtaposed group (data not shown, p<0.01). Six NUP98-t 
cases were identified among the 42 FLT3-ITD patients (14.2%), and they carried 
exclusively the t(5;11)NUP98-NSD1. No differences were found either in clinical features 
or survival between patients with isolated t(5;11) and those carrying the FLT3-ITD and 
NUP98-NSD1
11
. Finally, we confirmed the worse outcome and the higher cumulative 
incidence of relapse (CIR) of the NUP98-AML subgroup (N=22, EFS at 8 years=27.27%, 
CIR at 8 years=56.2%) compared to the entire Italian cohort of pediatric AML patients 
enrolled in the AIEOP AML-2002/01 protocol (N=460, EFS 56.3% Fig.1C, CIR=29.3% p-
value<0.01, Fig.1D). 
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Table 2. Clinical and molecular characteristics of selected AML cohort (N=172 molecular negative) for 
NUP98-t screening.Characteristics of NUP98-traslocated positive versus negative cases in the pediatric AML 
enrolled at the AIEOP AML-2002/01 protocol. Abbreviations: Y, years at diagnosis; WBC, white blood cell 
count; FAB, French–American–British classification; NA, not available; CR, complete remission.  
NUP98 rearranged patients expression profile. In order to characterize the new 
group of NUP98-t patients, we performed gene expression profiling using the new 
GeneChip® Human Transcriptome Array 2.0 (Affymetrix) for 19 NUP98 and compared 
them to 66 cases of de novo pediatric AML selected to provide a representation of the 
known morphologic, genetic, and prognostic subtypes. The unsupervised cluster analysis 
showed heterogeneity within AML either performed on the totality of probes (Fig.1SA), 
only on the coding transcript clusters (Fig.1SB), or the non coding portion (Fig.1SC) at 
exception of the AML1-ETO and MLL rearrangements, which clustered as previously 
reported
20,21
. Additionally, we identified the NUP98-t patients who gathered almost 
together revealing a new AML entity for gene expression (Tab.1SA-B, p-value<0.01). We 
then used a supervised analysis, and by analyzing  the coding transcript cluster we 
identified 76 differentially expressed mRNAs specific for the NUP98-t patients (fold 
change>|1.5|, p-value<0.01, Fig.2A, Tab.1SA). The most discriminative unregulated genes 
were implicated in protein trafficking (CPNE8, CPNE3), in cell cycle progression 
(CCNA1), in regulation of cell death (FAS) and, in agreement with other reports, most of 
NUP98-t, (%) AML molecular negative, (%) p-value
TOTAL 16 (9.3%) 156 (90.7%)
AGE, Y 0.33
<2 8 (50.0%) 54 (34.6%)
2-10 5 (31.2%) 46 (29.5%)
>10 3 (18.8%) 56 (35.9%)
SEX 0.57
Female 10 (62.5%) 86 (55.1%)
Male 6 (37.5%) 70 (44.9%)
WBC 0.28
<10,000 5 (31.2%) 62 (39.8%)
10,000-99,000 7 (43.8%) 74 (47.4%)
>100,000 4 (25.0%) 20 (12.8%)
FAB 0.70
M0 1 (6.2%) 19 (12.2%)
M1 4 (25.0%) 38 (24.4%)
M2 4 (25.0%) 18 (11.5%)
M4 1 (6.2%) 22 (14.1%)
M5 3 (18.8%) 29 (18.6%)
M6 0 (0.0%) 3 (1.9%)
M7 3 (18.8%) 18 (11.5%)
NA 0 (0%) 9 (5.8%)
Karyotype < 0.00001
Complex 9 (56.2%) 18 (11.5%)
Normal 7 (43.8%) 138 (88.5%)
CR 0.36
12 (75.0%) 131 (83.9%)
RELAPSE <0.01
9 (56.2%) 40 (25.6%)
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them belonged to the HOX family (HOXB5, HOXB4, HOXB6, MEIS1, NKX2-3
2,3,21,22
) or 
were genes such defensins (DEFA4)
23
. 
 Gene Ontology (GO) analysis in the NUP98-t showed enrichment in comparison 
with others AML in biological processes linked to the nuclear organization and 
chromosome assembling (regulation of mitotic metaphase/anaphase transition, of 
regulation of nuclear division, mitosis chromatin modification; Hypergeometric Test, p-
value<0.05, Fig.2B, Tab.2S). To confirm the fidelity of the microarray data, we validated 
the differential expression of several genes related to regulation of mitotic transition (such 
as CUL7, CUL9, HERC2), or to chromatin organization (KDM4B, CENPV and BCORL1) 
by RQ-PCR. All the analyzed genes were downregulated in NUP98-t patients consistently 
with the results obtained from microarray analysis (Fig.3S).  
We focused on genes of the HOXA and HOXB clusters, already known for their role 
in AML
24,25
, and we performed an unsupervised cluster analysis based on their expression. 
We revealed that their expression can split AML in three main branches: all the different 
NUP98-partners had a specific HOX signature, not only NUP98-NSD1 or JARID1A as 
previously reported
2,3
, showed an overexpression of HOXA and HOXB genes, clustering 
together with DEK-NUP214 rearranged patients and some molecularly negative cases. 
CBF rearrangements and FLT3-ITD mutation had a low or absent expression of both 
HOXA and HOXB genes, while MLL-rearranged cases were characterized solely by the 
presence of high HOXA genes (Fig.2C)
5,26,27
. Interestingly, concurrently to HOX cluster 
overexpression, we noted an upregulation of antisense transcripts genes belonging to 
HOXA (HOXA-AS4,-AS2,-AS3) and HOXB (HOXB-AS1,-AS2,-AS5) clusters within the 
NUP98-t patients. On the contrary, the remaining two groups lacked the expression of the 
HOXB antisense probes, while HOXA-AS overexpression was restricted to the MLL 
subgroup. 
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Figure 2. Gene expression analysis of coding transcript clusters in pediatric AML. A) Supervised 
hierarchical clustering analysis using the 76 differentially expressed coding RNAs identified among 19 
NUP98-t and 66 de novo AML patients (t-test, p-value<0.01). Genetic AML subtypes are indicated in the 
legend with color codes. B) Gene Ontology annotation of biological process enrichment of NUP98-patients 
performed on differentially expressed coding genes (p-value<0.05). Values on red column represent p-values 
while on blue column the number of genes, data are computed using Enrichr with the default association 
rules. C) Unsupervised cluster analysis of pediatric AML based on all HOXA and HOXB annotating probe 
sets present on the HTA 2.0 microarray. Genetic AML subtypes are indicated with color codes (as in panel 
A). Three cluster were observed as indicated by the different colors of the dendrogram (green=CBF 
rearrangements and FLT3-ITD mutation; blue= NUP98-t and DEK-NUP214, red= MLL-rearranged cases). 
Non coding RNAs in NUP98-t patients. Taking advantages of this new HTA 
platform, we could analyze the contribution of the aberrant expression of the non coding 
RNAs (ncRNAs), including small nucleolar RNAs (snoRNAs), microRNAs (miRNAs) and 
long ncRNAs (lncRNAs): 672 differentially expressed ncRNAs between NUP98-t and the 
AML cohort were revealed (p-value<0.01, Tab.1S). The ncRNAs most represented were 
lncRNAs (33%), followed by antisense RNA (22%), snoRNAs (15%), miRNAs (10%), 
snRNA (6%), rRNA (1%) and others unknown ncRNAs (7%) (Fig.3A). Most of the probe 
sets (610 over 672, 90.7%) were downregulated while just 62 ncRNAs were upregulated in 
p-value N of genes
B
C
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NUP98-t. Interestingly, miRNAs (11%) and snoRNAs (17%) were highly depicted in the 
downregulated RNAs and they were absent in the upregulated list. On the contrary, 
pseudogenes were mainly upregulated in the NUP98-t patients (31%) compared to the rest 
of AML (3%). Therefore, patients with NUP98-t had a strong and distinctive ncRNAs 
signature, highlighting the important function that those control deputy RNA might play in 
the NUP98-leukemia (Fig.3B).  
 
Figure 3. Gene expression analysis of non coding transcript clusters (ncRNAs) in pediatric AML. A) Pie 
chart show the 672 differently expressed ncRNAs identified by supervised hierarchical clustering analysis (t-
test, p-value<0.01) among the 19 NUP98-t and the 66 de novo AML patients. B) Heat map of hierarchical 
clustering analysis using the 44 most differentially expressed ncRNAs identified (t-test, p-value<0.01, 
FC>|1.5|). Genetic AML subtypes are indicated with color codes reported in the legend. C) (left) Gene 
Ontology annotation enrichment analysis for biological processes of coding genes negatively correlated with 
differentially expressed miRNAs (11%) in patients harboring NUP98-fusions (Pearson r<-0.4, p-value<0.01) 
and identified as targets in DIANA-microT web server computed using Enrichr with the default association 
rules. (right) miRNA-target interaction network shows interaction between the most deregulated miRNAs 
and their targets involved in the main biological processes such as mitotic cell cycle (in orange), mRNA 
processing (in blue), and nuclear transport (in yellow) 
 
 
N = 62 N = 610
A
lincRNA
pseudogene
antisense RNA
miRNA
snRNA
snoRNA
rRNA
other RNA
C
B
Term p-value
mRNA processing 0,0001
organelle assembly 0,0004
mRNA splicing, via spliceosome 0,0017
nucleobase-containing compound transport 0,0019
regulation of  centrosome cycle 0,0020
mRNA transport 0,0020
RNA splicing 0,0033
RNA transport 0,0038
stem cell maintenance 0,0044
proteolysis involved in cellular protein catabolic process 0,0045
nuclear export 0,0045
mitotic sister chromatid cohesion 0,0045
mitotic cell cycle 0,0056
modif ication-dependent macromolecule catabolic process 0,0091
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The 44 most expressed transcript clusters identified between the two sample groups 
(p-value<0.01; foldchange>|1.5|) were able to cluster NUP98-t patients and the other 
recurrent aberrations with the same strength of coding genes (Fig.3B; Tab.1SB). Among 
the top-ranking overexpressed ncRNAs, we identified some HOX antisense transcripts 
(HOXB-AS1, HOXA-AS4), and the pseudogene CCDC144B which is a well known stem 
cell marker
28
. In addition, we highlighted a strong downregulation of several members of 
the SNORD family belonging to a cluster located at 15q11 such as SNORD115, 
SNORD116, known to be implicated in hematological disorder
29,30
 (Tab.1SB). 
MicroRNA showed a general downregulation and, in order to investigate their 
involvement in NUP98-leukemogenesis, we correlated their expression levels with the 
upregulated genes of the NUP98-t being also predicted as microRNA targets by DIANA 
microT-CDS software
31
. We found significant negative correlations between 26 miRNAs 
and 167 predicted mRNA targets (Pearson correlation<-0.4; p-value<0.01, Tab.3SA). Gene 
Ontology (GO) analysis performed on these genes showed a significant enrichment in 
biological processes linked to nuclear organization and chromosome assembling in 
agreement with previous GO analysis from GEP (mitotic cell cycle, nuclear transport, and 
mRNA processing) (Hypergeometric Test, p-value<0.01). Cytoscape software was used to 
construct the miRNA-target regulation network involved in NUP98-t leukemogenesis 
(Fig.3C). Interestingly, in the differentially expressed miRNAs list, miR-513a was found 
as a key gene putatively involved in the control of several genes involved in all the main 
biological processes of the NUP98-t. In addition, we highlighted that miR-124, a miRNA 
already found involved in AML
32
, was inversely correlated to SNAI2, CDK13, ROCK2, 
FOXQ1, genes previously identified having a role in different cancers
33–36
.  
Partner genes characterization. Then, we investigated within the NUP98--t 
patients with particular attention to each fusion partner gene. We found 101 significantly 
differentially expressed transcript clusters (60 coding and 41 non coding RNAs, 
Tab.4SAB, Kurskal-Wallis test, p-value<0.01) among the NUP98 partners, revealing that 
each chimera could drive a different gene expression profile (Fig.4A). The same grouping 
was obtained either with the coding or the non coding genes (Fig.4SAB) supporting the 
importance of both transcript cluster classes in the NUP98-t AML. Interestingly, we found 
a distinctive expression of both the HOXA and HOXB cluster genes among the NUP98-t. 
The heat map depicted in Fig.4B showed that NUP98-NSD1 rearranged patients presented 
a specific downregulation of both the HOXA and HOXB genes compared to the rest of the 
NUP98-partners (Fig.5S).  
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To emphasized other partner driven differences, we compared, through Nearest 
Template Prediction algorithm (NTP), the significant enrichment of single patients with a 
list of molecular signatures related to NUP98-AML and cancer biological processes 
(Tab.5S) such as chromosomal instability, methylation, cell signaling and 
differentiation
3,10,17,22,37
. All partners, with the exception of PHF23, resulted to be more 
enriched in processes related to chromosome instability, while the former showed 
correlation to methylation
22
. Moreover, only JARID1A rearranged patients were enriched 
in megakaryocytic lineage as previously reported
3
. Focusing on the most represented 
partner in our cohort, the NSD1, we highlighted that it was mainly built up of signature 
involved in the translation initiation, indeed, among the top ranking overexpressed genes 
there was the eukaryotic initiation factors 4 (EIF4) as well as the Poly(A) Binding Protein, 
Cytoplasmic 1 (PABPC1); furthermore, the signatures involved in activation of CREB 
signaling
38,39
 (cAMP and GS3K)  as well as signature of dismal prognosis (Fig.4C) were 
found statistically significant when compared to the rest of interrogated signaling (Fisher 
test p-value<0.05).  
The identification of specific biological features associated with different NUP98-
translocation suggested that each partner drives a specific oncogenic signaling that may 
contribute to different prognostic implications. Indeed, the EFS of NUP98-NSD1, NUP98-
JARID1A and NUP98-PHF23 patients were 16.6%, 33.3% and 75% respectively (Fig. 6S, 
p-value<0.05) showing, among all fusions, the worst clinical outcome for NUP98-NSD1 
chimera and the best survival for NUP98-PHF23 patients. Even if survival analysis need to 
be validated in enlarged cohorts, our data cannot be ignored becausea follow up of 8 years 
contribute to consider reliable the prognostic value of at least the main representative three 
NUP98 partners. A more robust analysis confirmed that NUP98-NSD1 presented the worst 
EFS compared to the remaining groups, that may be differently considered for a less severe 
clinical management (Fig.4D, p-value<0.05). 
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Figure 4. NUP98 partner genes clustering analysis. A) Supervised hierarchical clustering analysis using the 
101 probe sets identified by Kruskal-Wallis test among 19 NUP98-t patients (p-value<0.01) that comprehend 
2 t(11;21)(p12;p13)NUP98-JARID1A, 11 t(5;11)(q35;p15.5)NUP98-NSD1, 3 t(11;17)(p15.5;p13)NUP98-
PHF23, and 3 others fusion (1 t(2;11)(q31;p15)NUP98-HOXD13, 1 t(9;11)(p22;p15.5)NUP98-LEDGF and 1 
inv(11)(p15q22)NUP98-DDX10). Different NUP98 partner genes are indicated below the dendrogram with 
different colors. B) Unsupervised cluster analysis of pediatric NUP98-t patients based on all HOXA and 
HOXB clusters annotating probe sets present on the HTA 2.0 microarray. (C) The presence of significant 
Molecular Signature DataBase (MSigDB p-value<0.05) gene patterns identified by 
NearestTemplatePrediction (NTP) algorithm are indicated by black boxes (*p-value<0.05 by Fisher test for 
NUP98-NSD1 versus others). D) Event-Free Survival (EFS) calculated for patients which harbor NSD1 as 
partner gene (N=12) or JARID1A and PHF23 as partner genes (N=7). The difference between Kaplan-Meier 
curves results statistically significant (Log-rank test, p-value<0.05).  
CREB directly targets NUP98 chimeras. The most important signaling enriched 
in NUP98-NSD1 patients was the cAMP/CREB
38,39
, an important pathway already 
described contributing to leukemia
40–42
. CREB is a transcription factor with several binding 
sites in NUP98 promoter (CRE region around 1300 bases before NUP98 transcription start 
site; Match ver 1.0 tool analysis, TRANSFAC MATRIX TABLE, Release 7.0, Fig.5A) and 
we confirmed its transactivational role by chromatin immunoprecipitation in AML cell 
lines (HL60 and U937)(Fig.5B). Furthermore, a luciferase reporter gene (LUC) being 
under the control of NUP98 promoter, confirmed CREB dependent modulation of the 
reporter gene expression (Fig. 5C). Results showed that reporter activity (pXP2-
NUPPROM) significantly decreased in combination with CREB silencing compared to 
controls (either the vector alone ,pXP2; the vector with CRE mutated sequence,pXP2-
NUPPROM CREB BS MUT: and siRNA CTR). In particular, after 24h of CREB siRNA 
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transfection, LUC activity was decreased. On the other hand, an increase in LUC activity 
was seen following CREB overexpression (pEGFP-flagCREB) in comparison with 
controls (pXP2, pXP2-NUPPROM CREB BS MUT)(Fig.5C), all results were double-
checked by western blot analysis (Fig.5D).  
 
 
 
Figure 5. CREB regulates NUP98 endogenous expression. A) A schematic structure of NUP98-promoter 
1300 bases before transcription start site identified by Match ver 1.0 tool analysis, TRANSFAC MATRIX 
TABLE, Release 7.0. The wild type (top) and the mutated (bottom) sequence of the cAMP response element 
(CRE) recognized by CREB, is highlighted in the box. Mutations in the sequence were inserted between the 
nucleotides 3-6. B) PCR of the 200-bp NUP98 promoter fragment amplicon after chromatin 
immunoprecipitation (ChIP) for CREB in AML cell lines, HL60 and U937 (input=cell lysates before 
immunoprecipitation; CTR+=cell line DNA; IgG is the negative control of ChIP, mock= PCR mix without 
DNA). C) The portion of the wild type CRE promoter depicted in the cartoon was cloned in the LUC vector 
pXP2-NUP98prom, while the mutated one in pXP2-NUP98prom CRE mut. Luciferase (LUC) activity was 
measured in HEK293T transient cotransfection of pXP2-NUP98prom with siRNA CREB/siRNA NEG or 
with pEGFP-flag-CREB plasmid to silence or overexpress CREB respectively. The vector alone (pXP2) or 
the mutated CRE vector were used as controls. Results show a significant decrease and increase in LUC 
activity after CREB levels modulation (N= 3, normalized with Renilla (REN) activity). D) Representative 
Western blot analysis of NUP98 protein level after CREB silencing (siRNA CREB) or overexpression 
(pEGFP-flag-CREB) in HEK293T cell line. NUP98, CREB and β-ACTIN proteins were revealed.  
Given the fact that NUP98 maintains its N-terminus during somatic translocation, 
its promoter guide fusions expression
1
, and CREB can be considered the candidate in 
maintaining chimera expression along AML course. To substantiate this hypothesis we 
engrafted NSG mice with patients harboring t(5;11)NUP98-NSD1 translocation and, after 
confirming the same leukemia phenotype of diagnosis, we silenced CREB gene. Twenty-
four hours and 48h post CREB silencing (RQ=0.5, Fig.6A), we attested a strong reduction 
of NUP98-NSD1 expression (RQ =0.03) and of some of its target genes. NUP98-NSD1 
protein showed the same reduction seen for mRNA since 24h (Fig.6B). Cells were 
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confirmed to increase apoptosis and reduce clonogenicity after CREB and chimera 
reduction levels, as expected (data not shown)
14,19,41,43
. 
 
Figure 6. CREB silencing in NUP98-AML cultures. A) Decrease of NUP98-NSD1 mRNA levels 24 and 48 
hours post CREB silencing was detected by RQ-PCR (RQ=1 for siRNA NEG, N=3, p-value<0.05). B) 
Western blot analysis confirmed the reduction of NUP98-NSD1 chimeric protein levels in primary cell lines 
after CREB silencing, number in the figure represent the densitometric quantification mean of Western blot 
band normalized to siRNA NEG (N=3, p-value<0.05)  
NUP98-NSD1 enhance genome instability. To gain into the leukemogenic role 
mediated by these NUP98-chimeras we used results obtained by GEP and GO, where 
chromosome instability was revealed as one main feature. The previous observation that 
NUP98-HOXD13 overexpression in fibroblasts caused substantial perturbation of 
chromosome segregation
17
 together with the fact that almost the 60% of NUP98-
translocated patients presented a complex karyotype at diagnosis, forced our attention on 
this mechanism. In vitro studies on NUP98-NSD1 primary cells and healthy bone marrow 
(HBM) were conducted. Cells were arrested in M phases by treatment with the 
microtubule-depolymerizing drug nocodazole and harvested at different time point (0-24h) 
to analyze spindle assembly checkpoint (SAC) defects in total cell extracts. Western blot 
analysis showed since 8h of treatment a decrease in MAD2 and BUB1 protein levels 
compared to healthy bone marrow cells, confirming the lack of control on sister chromatids 
separation in NUP98-translocated cells. Indeed, an increase in the expression of Cyclin B 
is revealed at the same time points, indicating an early and uncontrolled entrance in mitosis 
for leukemic cells (Fig.7A).  
To address the possibility that NUP98-t chimera are more prone to chromosomal 
double strand break, we blocked DNA replication by exposing cells to aphidicolin (APH) 
treatment and measured the number of mitotic chromosomal breaks 24h post treatment. 
NUP98-translocated cells exhibited more visible chromosomal breaks (Fig.7B). This latter 
result was confirmed by western blot analysis, after 24h of APH treatment, PP2A β subunit 
A B
siRNA
NEG
siRNA
CREB
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was found in the cytoplasm, with a consequent increase in H2AX phosphorylation 
(γH2AX) more evident in the NUP98-t cells. In response to genotoxic stress, in fact, PP2A 
translocate into the cytoplasm, allowing the activation of ATM which in turn 
phosphorylate H2AX, the docking site for DNA repair enzymes recruitment. Interestingly, 
only in HBM cells the γH2AX was detected in the cytoplasmic fraction to sustain the 
incapability of healthy cells to survive after a strong not repaired DNA damage, activating 
the apoptotic pathway (Fig.7C)
44
. 
 
 
Figure 7. NUP98 fusion oncoproteins cause genomic instability. A) Western Blot analysis showing a 
decrease of mitotic proteins levels in nocodazole treated NUP98-NSD1 rearranged primary cells and HBM. 
Cyclin B1 (CCNB1), mitotic arrest deficient 2 (MAD2), and BUB1 were detected impaired in t(5;11). B) 
Dual color FISH analysis using a red probe for NUP98 and green probe for NSD1 in ex vivo NUP98-NSD1 
cells. To evaluate the Frequency of chromosomal aberrations (CAs) 50 mitosis for each cases were counted. 
G-banded karyotype showing the chromosome aberrations (arrows) in NUP98-NSD1 primary cells and HBM 
before and after treatment with aphidicolin (APH) for 24h at 0.05μM are shown. C) After APH treatment the 
expression of PP2A-B55α in the cytoplasm and γH2Ax in the nucleus of NUP98-NSD1 primary cells 
measured by western blotting revealed chromosome instability; whereas cytoplasmic γH2Ax in the HBM 
confirmed activation of apoptosis  
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DISCUSSION 
In the era of personalized therapy, where specific molecule can be targeted, it is 
becoming increasingly important to identify genetic abnormalities that may dictate the 
disease and treatment course
45
. However, despite recent progresses in the identification of 
molecular lesions, still more than the 50% of patients with AML lack of a known genetic 
biomarker at diagnosis, remaining a heterogeneous disease
46,47
. The outcome of children 
with AML has significantly improved over the past two decades, however a remarkable 
contribution to the cure has been given only by the wide use of hematopoietic stem cell 
transplantation, since chemotherapy consisting in repeated courses of intensive 
consolidation has not been changed. Thus, the identification of novel prognostic and also 
therapeutic markers constitute an urgent need to overcome AML obsolete cure and 
improve children outcome. 
In this study, we pursued the discovery of new biomarkers for pediatric AML at 
diagnosis focusing on NUP98 gene, and then we tried to dissect the mechanism of action to 
indicate novel targeted strategies. Results revealed that NUP98 rearrangements were not 
rare events (4.6%) among Italian children with leukemia, and identified, both clinically and 
biologically, a new relevant class of pediatric AML with severe prognosis and specific 
leukemogenic process. NUP98-rearrangements incidence is comparable with those 
identified by the Japanese (4.8%) and the BFM cohort (5.7%) that took in consideration 
only the t(5;11)(q35;p15.5)NUP98-NSD1, with the addition of t(11;21)(p12;p13)NUP98-
JARID1A just for the BFM
2,3,21
. Indeed, NUP98-NSD1 is the majorly found rearrangement 
also in our cohort, that is also characterized by other five partners gene. NUP98-
rearrangements have been considered type II abnormalities
4
 to impair the differentiation 
process , and according to Kelly and Gillard hypothesis
48
, an additive type I abnormality, 
such as FLT3-ITD or RAS mutations
2,4,10,49
 may occur to develop full-blown leukemia. 
Interestingly, in our cohort we found FLT3-ITD exclusively within the NUP98-NSD1 
rearranged patients, as Hollink et al.
2
 and in contrast with Taketani et al.
10
 that found 
FLT3-ITD mutation in other NUP98-translocations, probably due to the uniqueness of the 
Japanese leukemia
10
. However, in our study, others collaborative type I events, such as N 
RAS, K RAS, IDH1 and c-KIT mutations were never found in the whole cohort of NUP98-
rearranged patients, and new mutational events that could contribute to leukemia with 
NUP98 translocations remains to be elucidated. Altogether, NUP98-patients were 
characterized by a detrimental clinical outcome, with a higher than expected frequency of 
relapse (60%), also if compared with high risk AML
12
, suggesting that current therapy has 
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a very low efficiency in blasts clearance, contributing to disease recurrence. Moreover, we 
did not find any difference in either clinical or biologic features between patients with 
isolated t(5;11) and those with t(5;11) and FLT3-ITD, sustaining that the chimera 
superimposes its role in determining the leukemia gene expression profile and 
aggressiveness. Nevertheless, the type of partner gene confers specificity in defining 
patients outcome
2,3,11
, indeed, those harboring t(5;11) present the worst survival, while 
those characterized by NUP98-PHF23 display a better prognosis. Prospective and 
cooperative studies are desirable to confirm these results and improve risk stratification 
within NUP98-rearranged patients. 
Here, we attempted to comprehend if differences in outcome found within the 
NUP98-subgroups could be explained by a different tumor biology. We interrogated gene 
expression profiling trying to find candidate genes involved in NUP98 translocations. In 
the last decades, there has been an effort to integrate gene expression globally in AML 
prognosis; the identification of distinct gene expression signatures has already showed its 
impact on patients’ clinical management, including determining sensitivity to specific 
therapies
13,50,51
. Here, NUP98-rearranged patients were revealed to have a specific coding 
and non coding gene expression profile, confirming the homogeneity of this newly 
identified AML entity with respect to the rest of AML, such as CBF-MLL-NUP214-
rearranged as well as FLT3-ITD and the rest of molecularly negative AML. This is the first 
time where a specific non coding signature is given for a comprehensive expressional 
study of all the non coding RNAs (ncRNAs) among pediatric AML. We revealed that 
ncRNAs signature clustered NUP98-t patients and others known cytogenetic AML 
subgroups at the same strength of coding genes, although sustaining the role of ncRNAs as 
important mediators of the AML phenotype
52–54
. This analysis revealed that microRNAs, 
the most characterized ncRNAs class
14,30,55–57
, were found significantly downregulated in 
NUP98-t patients with respect to the rest of AML. Therefore, we hypothesized that their 
downregulation may explain the uncontrolled expression of putative oncogenes in NUP98 
leukemias. By correlating microRNAs and gene expression we generated a list of new 
candidate couples of tumor suppressors and oncogenes that may be involved in NUP98 
mediated leukemogenesis. Among them, we consider miR-513a the most intriguing 
microRNA for its role in different biological process involved in NUP98-t patients, as well 
as for its previous role found in the block of cellular differentiation in other cancers
58,59
. 
Functional studies should be conducted to address if miR-513a could be a good therapeutic 
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candidate in this AML context
60
, and which is or which are its putative targets among the 
several overexpressed genes found in NUP98 leukemia. 
Looking for biological processes enriched in the NUP98-t patients, the gene expression 
signatures of both coding or non coding probes converged in the identification of the 
regulation of mitosis and chromosome segregation
17,61–63
. Thus, moving on NUP98-t 
primary cells, we observed uncontrolled mitosis in the presence of an unsatisfied spindle 
assembly complex, and we detected a higher number of chromosomal breaks and an 
increased protein levels involved in DNA damage in response to genotoxic stress. On the 
contrary, same treatments performed in healthy hematopoietic cells correlated with an 
accumulation of a pro-apoptotic signal due to the translocation of γH2AX in the cytoplasm, 
and lead to cell death
44
. All these findings converged to sustain that DNA repair, 
chromosome segregation and cell cycle control, already known for their role in genomic 
instability and in tumors cell biology
64,65
, are processes straightly involved in NUP98 
leukemogenesis. In proof of these deregulated processes, we highlighted that NUP98-
translocated patients present in the 56.2% of cases a complex karyotype compared to the 
11.5% of the rest of AML. It is thus tempting to speculate that the progressive genomic 
instability observed in these NUP98 model, due to failure of DNA repair and to spindle 
assembly defects, may be the pivotal mechanism leading to the acquisition of cooperating 
molecular aberrations that may lead to disease progression from MDS to leukemia
7,66,67
. 
However, the exact underlying mechanism that takes place in NUP98 leukemia will 
require further investigations, but these novel findings sustain the chimeras role mediating 
different leukemogenic pathways as previously proposed
68
. 
 In fact, NUP98, like MLL, has many partner genes characterized by different 
domains that define the leukemogenic potential of the fusion
68,69
. In our cohort we 
identified 6 partner genes: 3 of them, the most frequent, NSD1,PHF23 and JARID1A, 
present a chromatin recognition domain (PHD) designated to interpret H3K4me3 
marks
22,70
 while the other partners are constituted by DNA binding domain as a 
homeodomain (HOXD13)
9,68
 or coiled-coil domain (LEDGF and ADD3)
1
. Of note, we 
evidenced the overexpression of HOX genes in NUP98 rearranged patients compared to the 
rest of AML cases as already reported in other cohorts 
2,3,22
. Since now, the deregulation of 
the HOX genes has been straightly correlated with leukemogenesis of NUP98-chimeras
4
. 
Nevertheless, by studying HOX A and B genes expression among different NUP98-
chimeras, we revealed that in NUP98-NSD1 cases their expression was extremely lower 
suggesting that probably others co-operating oncogenic processes are occurring to cause 
124 
 
this aggressive type of leukemia. In particular, NUP98-NSD1 patients were found 
particularly enriched for CREB signaling
38,39
. This important network has been validated in 
patient’s primary cells: CREB was revealed to directly control NUP98 promoter; its 
silencing severely decreased NUP98-NSD1 chimera and its target genes expression, finally 
proving that CREB controls the transcriptional regulation of NUP98-NSD1. The finding 
points to possible CREB-NUP98 axis as pivotal leukemogenic mechanism in this NUP98-
AML subgroup, that together with chromosome instability, define a novel mechanisms in 
the pathogenesis of this disease. In conclusion, the identification of NUP98 rearrangements 
as not rare biological and clinical entity in childhood AML raises important improvements 
in the genetic landscape and management of pediatric AML. The specific gene expression 
profiling such as a different clinical outcome for each partner gene reveal a distinct nature 
of each subtype of NUP98-rearranged AML. CREB involvement and the enhanced 
genomic instability among these patients opens for further evaluation on the leukemogenic 
role of NUP98-NSD1 oncoprotein, that can be determinant for the aggressive nature of this 
leukemia. The identification of this mechanism unclose new therapeutic strategies, such as 
CREB inhibitors, combined with conventional therapy to improve the outcome of these 
subsets of childhood AML. 
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SUPPLEMENTARY INFORMATION 
Supplementary methods. 
Gene expression analysis. Briefly, 100 ng of total RNA were labeled and 
hybridized to Affymetrix GeneChip® Human Transcriptome Array 2.0 (HTA 2.0) for 16 h 
at 45°C using a rotational oven and washed according to Affymetrix standard protocols 
using a GC450 Fluidics Station. The Genechips were scanned with an Affymetrix 7G 
scanner and the CEL files generated were analyzed through Affymetrix Expression 
Console Software (version 1.3) which normalizes array signals using a robust multiarray 
averaging (RMA) algorithm. Probes were re-annotated using GENECODE v.19 gene 
annotation database (www.genecodegenes.org)
1
 in order to identify both coding and non-
coding RNAs covered by probes. Transcripts were included if at least the 95% of 
nucleotides overlapped with probes. In miRNA analysis, for every probe which recognizes 
pre-miRNA, we used both associated miRNA mature, where available. Normalized data 
were analyzed using GENE-E analysis platform (Broad Institute of Harvard and MIT, 
Boston, MA). Cluster analysis was performed using distances based on Pearson 
Correlation or Spearman Rank coefficient. An unpaired t-test was applied to identify 
differentially expressed genes between sample pairs and probes with P-values less than 
0.01 were declared significant. 
Gene functional enrichment analysis. We examined whether the differentially 
expressed genes are biologically meaningful via functional enrichment analysis using the 
integrative web-based software Enrichr
2
. This tool enables the detection of significant 
enrichment for a set of genes in Gene Ontology (GO) Consortium database. We used the 
whole human genome as a reference set for enrichment analysis and applied a 
hypergeometric test with a significance level of p ≤0.05. To understand which biological 
processes were regulated by differentially expressed miRNAs, we identified the predicted 
miRNA–target interactions through DIANA microT-CDS software3 with a prediction 
threshold of 0.8. We examined the Pearson's correlation (r) of miRNA-target pairs with 
micrographite R package
4. Only pairs with r < −0.4 and p-value < 0.01 were considered 
negatively correlated. Gene identified were undergo to functional enrichment analysis as 
previously described. miRNA-target interactions network was designed through Cytoscape 
v3.3.0 software
5
. 
Gene Set Enrichment Analysis (GSEA) software version 4.0
6
 was used to identify 
gene sets in the public domain that share the expression pattern found in the NUP98 
translocated patients respect to an eterogeneous cohort of pediatric AML patients. For each 
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group of gene sets, GSEA calculates and evaluates the statistical significance of an 
enrichment score (ES). The ES reflects the degree to which a gene set is over represented. 
We compared the gene expression signatures collapsing the probe sets to gene vectors and 
using the signal-to-noise metric, the gene-set permutation type and 1,000 permutations. As 
recommended by GSEA guidelines, only gene sets with a P-value < 0.05 and a false 
discovery rate (FDR) q-value < 0.25 were considered. 
For help with interpreting the gene set  enrichment  analysis  go  to 
http://www.broadinstitute.org/gsea/doc/GSEAUserGuideFrame.html%20Interpreting_GSE
A_Results. The NearestTemplatePrediction algorithm (NTP)
7
 implemented as module of 
the Gene Pattern software (Broad Institute of Harvard and MIT, Boston, MA) was used to 
predict the proximity of the expression pattern of molecular signatures deposited in the 
Molecular Signature Database (www.broadinstitute.org/gsea/msigdb) to each single 
patient's gene-expression data using cosine distance. Only prediction with statistical 
significance (p-value < 0.05) were used for the heatmap generation. 
Primers sequences  
NUP98F GCTGGACAGGCATCTTTGTT 
NUP98 988F ACCAGCCTCTTCAGCAAACCATTTG 
NSD1 R1 TGCACCTGCTCCTGTACCTTC 
NSD1 R2 TCCAAAAGCCACTTGCTTGGC 
NSD3 R1 AATGCTTTCTCTGCATGGGC 
NSD3 R2 CACAGATCTTGGTCGTCGGG 
JARID1A R1 TAGCTTCCGTTTCCGTTTCT 
JARID1A R2 TCAGCTCCTTTGATTTGTCT  
PHF23 R1 GGCCCCAGTAGCTTTGACAGAT 
PHF23 R2 GCAGACGAGAGAAAGTGGACCT 
HOXA9R1 CCTGCGGTCCCTGGTGAGGT 
HOXA9R2 GCACCGCTTTTTCCGAGT 
HOXD13 R1 CAGGAGACAGTATCTTTGAGCTTGG 
HOXD13 R2 AAGCTGTCTGTGGCCAACC 
HOXC11 R1 TGCAGCCGCTTCTCTTTGTT 
HOXC11 R2 TTACAGCAGAGGATTTCCCG 
ADD3 R1 ACCTACTCACTCGCTTAGCA 
ADD3 R2 CTTCTTCGATTTTCTCTGGAGACTT 
HHEX R ATTTAGCGCGTCGATTCTGA 
HHEX R1 TCTCGGGCGGAGAGAGATATT 
DDX10 F AAATATACTCGTGTGCACACCAGG 
DDX10 1078 R TGCTCTTCTTCTTCAGATGGCTTC 
LEDGF R AACAGATGCTGTTGCTGTTGTCAC 
NSD3 R AATGCTTTCTCTGCATGGGC 
LOC348801 R TCTCTCCTTTCTGCTTTCAGGT 
LOC348801 R2 AAGAGGCAGAACGCTTGGTT 
NUP98 CHIP  F AGTTACCATGCCATTCTGGGG 
NUP98 CHIP  R CATTGGGCAACGCGTCTTTT 
CREB F CGGTGCCAACTCCAATTTAC 
CREB R ATTGCTCCTCCCTGGGTAAT 
NUP98 F RQ-PCR CCATCTATGGATGACCTTGCTAAA 
NUP98 R RQ-PCR TCCGACCAATAGTGAAATCAGAGA 
CUL7 F RQ-PCR CCTACCTGAGGGGCACTTTG 
CUL7R RQ-PCR CGCCTTCAGGTCGTTGAGAT 
NUP98-NSD1 F RQ-PCR CTTGTACAGGAGCCTTTGG 
NUP98-NSD1 R RQ-PCR GGCTTCCTAAGGCGTTTCTT 
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Suplementary figures 
 
Figure 1S. Unsupervised clustering of pediatric de novo AML. Cluster analysis using Spearman correlation 
distance among the gene expression profiles of 85 de novo pediatric AML samples (p-value<0.01). Samples 
are color-coded according to their cytogenetic subtype. The heatmaps identify 3 probe matrix : A) Total 
RNA, B) coding RNA C) non-coding RNA. 
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Figure 2S. Gene expression profile of 19 NUP98-traslocated patients. A) Supervised hierarchical clustering 
analysis using the 1291 probe sets identified among 19 NUP98-t and 66 de novo AML patients. B) Heat map 
of the 120 probe sets most differentially expressed (FC>1.5) between NUP98-t and all AML rearrangements 
studied. The genetic subtypes were indicated with color codes. The differently expressed genes between the 
two groups were identified by gene selection based on t-test (p-value<0.01).  
 
Figure 3S. Real time quantitative-PCR (RQ-PCR) validation of microarray data. Six genes were selected to 
validate microarray data by real time-PCR. CUL7, CUL9, HERC2 are related to regulation of mitotic 
transition while KDM4B, CENPV and BCORL1 are involved in chromatin organization. cDNAs from bone 
marrow of 19 NUP98-t patients and other 22 de novo AML (including patients with core-binding factor 
aberrations, MLL rearrangements, t(6;9)(p23;q34)DEK-NUP214 and negative for known recurrent genetic 
abnormalities previously described) were used for the RQ-PCR reaction. RQ expression, calculated with 2^-
DDCt of genes in 19 NUP98-t patients compared to other AML (RQ=1) is presented 
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Figure 4S. Coding and non-coding RNA cluster analysis of NUP98-AML patients. Supervised hierarchical 
clustering analysis using A) the 60 differentially expressed coding RNAs and B) the 41 non-coding RNAs 
identified among the 19 NUP98-t patients (Kruskal Wallis, p-value<0.01). Different NUP98 partner genes 
were indicated below the dendrogram with different colors: blue for JARID1A, red for NSD1, green for 
PHF23 and yellow for other partner genes. 
 
 
Figure 5S. HOXA genes expression in NUP98-t patients. Box Plot of HOXA genes expression in patients 
harboring NSD1 (N=11) as partner gene versus others NUP98-t positive patients (N=8, p-value<0.05). 
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Figure 6S .Probability of event-free survival (EFS) in NUP98-AML characterized by different partner genes. 
EFS was calculated for patients with NUP98 and NDS1, JARID1A and PHF23 (p-value<0.05) at 8 years of 
follow up. 
 
 
  
CHAPTER 5 
 
 
 
 
 
 
Conclusions 
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Acute leukemia is the most common form of pediatric malignancy and numerous 
events are currently known to occur and finally contribute to promote the onset of this 
disease. Despite leukemias have been well characterized from the genetic view point, acute 
myeloid leukemia (AML) remains the most heterogeneous disease with just the 50% of 
patients presenting an available biomarker that can direct therapy and guide prognosis
1,2
. 
During this PhD my main interest was to increase the number of molecular markers 
available for pediatric AML patients, considering a large cohort of AML enrolled in 
AIEOP-LAM 2001-02 protocol from 2002 to 2012
3
.  
At first, I evaluated the incidence of rare genetic abnormalities in pediatric AML 
such as del(4)(q12)FIP1L1-PDGFRA, t(16;21)(p11;q22)FUS-ERG, t(8;16)(p11;p13)MOZ-
CBP, t(11;17)(q23;q12-21)MLL-AF17, t(4;11)(q35;q23)MLL-ARGB2, MLLPTD 
t(5;11)(q35;p15.5)NUP98-NSD1 and t(3;5)(q25;q34)NPM1-MLF1. These rearrangements 
were described mainly as case reports in literature but their incidence in a pediatric cohort 
was never considered. Thanks to the large retrospective screening I established that the 2% 
of cases presented the t(3;5)(q25;q34)NPM1-MLF1, the 1.3% of patients harbored the 
t(8;16)(p11;p13)MOZ-CREBBP, while 2% carried MLLPTD. These results reveal that such 
rearrangements remain rare in the pediatric field, however further prospective studies will 
permit to enlarge these small cohorts of new AML subgroups, allowing in the near future 
their characterization also for a prognostic value. The best result was obtained for the 
translocation t(5;11)NUP98-NSD1, which reached an incidence of 4% in AML patients, 
and moreover was found associated to the FLT3-ITD mutation. I established that also in 
the Italian cohort this marker is associated to a very low survival, as previously reported 
for another European cohort
4
.  
Then I also evaluated the incidence of c-KIT mutations, already known to occur in 
different cancers as well as in adults AML
5,6
. I considered a selected group of AML, the 
CBF-rearranged, because c-KIT mutations were previously found frequent within patients 
harboring these molecular lesions
7
. I confirmed a strong incidence of c-KIT mutations in 
pediatric patients with the t(8;21) RUNX1-RUNX1T1 (25%), and with the inv(16)/t(16;16) 
CBFB-MYH11 (18.5%). The predictive value of a worst outcome of c-KIT mutations was 
confirmed only for the t(8;21) patients. This result permits the identification of a group of 
patients, within the same genetic background, with a higher risk of relapse and that may be 
considered for alternative therapeutic strategies. 
Finally, these molecular screenings performed at diagnosis of AML confirmed that 
the identification of a marker is mandatory for a more precise patient stratification in 
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appropriate risk class with the final aim to better manage their cure and improve their 
survival. 
Then I evaluated if the crucial role of a molecular marker at diagnosis could persist 
also during therapy course. At first, I focused on the Italian standard-risk (SR) group of 
patients, as defined by the protocol AIEOP 2002/01 harboring the isolated CBF-
rearrangements, in which the outcome was found less than the expected
3,8
. I performed the 
molecular monitoring of minimal residual disease (MRD) levels after induction 
chemotherapy for both, the RUNX1-RUNX1T1 and CBFB-MYH11 fusion transcripts. 
Results revealed that MRD levels provided reliable prognostic parameters to manage 
therapy decisions also in childhood AML, in particular for the RUNX1-RUNX1T1 
rearranged patients. I reproduced the same results when molecular MRD levels after 
induction were measured on FLT3-ITD marker.  
These new findings on the role of molecular MRD, contribute to overcome the lack 
of studies on post-treatment monitoring of genetic abnormalities and confer, also in 
pediatric AML, a new role to MRD molecular monitoring.  
 
I dedicated most of my PhD to perform clinical translational research: this branch 
of medical science aims to expedite the translation of scientific discovery into new or 
improved standards of care. This definition fit well with my personal feeling that drove my 
PhD experience towards a research that has to be instrumental to improve children survival 
and fight cancer. When a molecular marker is defined for its diagnostic role, it is important 
to underpin the leukemogenic and biological mechanism involved with it. With this aim, I 
performed several investigations to better comprehend FLT3-ITD mutation, MLL-AF6 
fusion, and the NUP98-rearrangements.  
The first functional study was a comprehensive study on FLT3-ITD mutation in a 
large pediatric AML cohort (482 patients) enrolled in a single clinical protocol
3
. We tried 
to discuss the significance of the allelic burden of the mutation, as well as the minimal 
residual disease after induction treatment, and defined both features as strategic tools to 
refine risk stratification and direct pre-emptive therapy. We used this two parameters to 
divide patients in two groups and investigated the disease biology by gene expression 
profile. Results revealed that patients with high allelic ratio of ITD mutation as well as 
persistent residual disease activated different signaling pathways concerning methylation, 
acetylation, and the CyclinA1/cMYB oncogenic pathway. These findings open for further 
experimentation of novel epigenetic drugs, combined with conventional strategies, that can 
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be adopted to improve the survival of a subgroup of FLT3-ITD patients who shares a high 
risk of relapse and die
9,10
. 
The investigation on MLL-AF6-rearranged patients was suggested by the very low 
percentage of survival that this marker conferred to this subgroup of AML (22% at 8 
years)
11,12
. The functional study was addressed to comprehend the role of the chimera in 
order to find new targeted therapies. Results demonstrated that the cytoplasmatic 
interaction of AF6 and RAS was responsible to maintain low levels of RAS-GTP in 
hematopoietic cells, while the occurrence of MLL-AF6 resulted in an de-localization of 
AF6 into the nucleus with the consequent RAS activation, which contributed to the 
aggressiveness of this leukemia subtype. These findings were confirmed in vitro, where we 
used specific RAS-inhibitors to increase AML blasts susceptibility to death. A new era of 
new therapeutic opportunities against RAS signaling can be supported for this subgroup of 
leukemia with a very detrimental destiny. 
The last functional study sought to refine the role of various NUP98-
rearrangements found in pediatric AML
4,13
. The fact that NUP98 can arrange with several 
genes is extremely interesting: above all because it reflects the properties of MLL, one of 
the key-gene in pediatric leukemia. To discover if NUP98 plays a leading role in AML, I 
looked at several fusions involving its N-terminus with the C-terminus of HOXC11, 
HOXA9, HOXD13, HHEX (sharing a HD domain), LEDGF, DDX10, ADD3, LOC348801 
(sharing a CC domain), and NSD3, JARID1, PHF23 (sharing a PHD domain)
14,15
. All 
together, these aberrancies allowed to define a novel Italian NUP98-AML subgroup (4.6%) 
with dismal outcome. Then, biological implications were interrogated in order to dissect 
the mechanism of action of NUP98 translocations. I found a unique expression pattern with 
both coding and non coding transcripts with respect to other AML selected to provide a 
good representation of the known morphologic, genetic, and prognostic subtypes of de 
novo pediatric AML. Genes enrichment analysis showed that NUP98-AML were 
particularly characterized by processes correlated to nuclear organization and 
chromosomes assembly. By gene expression analysis I also established that the NUP98 
partner gene drove a specific gene signature as well as a different outcome. In vitro 
analysis chromosome instability being involved in this type of leukemia was confirmed, 
and also I revealed CREB as the transcription factor responsible for the chimera 
expression. This study provides important clinical and biological implications: such as the 
identification of new markers at diagnosis that can assign patients to specific risk-classes to 
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overcome their dismal prognosis, and the definition of the leukemic mechanism behind 
NUP98-oncoprotein that could be targeted to improve patients cure. 
 
In conclusion of this PhD, I can sustain that pediatric AML is still a very 
heterogeneous disease. The discovery that within the same genetic group, that is expected 
to present a concordant outcome, it is possible to identify a wide spectrum of additive 
markers, at diagnosis and during follow up, that concur in defining new and distinct 
prognosis, reveals a even more complex picture of pediatric AML. The fact that most 
differences in clinical outcome can derive from differences in response to therapy, and that 
it is often guided by a specific patient-biology support the further evaluation of the crucial 
role of defining a even more personalized therapy to improve children survival. The fact 
that some of my results have been included in the AIEOP LAM 2013 protocol and consist 
in the characterization of new markers that will improve the risk stratification at diagnosis 
for a subset of Italian patients ( e.g. FUS-ERG, NPM1-MLF1, MLL-ARGB2, NUP98-
NSD1, c-KIT) and refine post-remission course thanks to disease monitoring during follow-
up (e.g. RUNX1-RUNX1T1 and FLT3-ITD) (figure 1) confers to this PhD great 
satisfactions.  
Notwithstanding the effort spent in identifying new markers, still a large part of 
patients remains not characterized for the genetic aberrations that induced their leukemia. 
Therefore, the application of high throughput technology will likely accelerate our insight 
in the genetic landscape of AML allowing the identification of new aberrations. 
Deciphering the functional consequences of the abovementioned aberrations still remains a 
challenge, that has to be explored in order to develop new therapies to improve the 
outcome of pediatric AML as I found for MLL-AF6 and NUP98-rearrangements. Indeed, 
the preliminary  results that suggest a more personalized therapy, such as RAS inhibitors or 
CREB inhibitors, may be deeply investigated to change the fate of these subsets of 
childhood AML. 
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Figure 1. Estimated frequency of genetic abnormalities in childhood AML in the Italian population. The 
most common karyotypic alterations are shown in the center, the others are made up of recently identified 
rare abnormalities. (Right) Mutational profile of patients without cytogenetic abnormalities (normal) and the 
incidence of cKIT mutations in t(8;21) rearranged patients; 43.1% of those in the normal population have one 
of the known mutations. The most frequent MLL partner genes found in AML Italian cohort are also shown. 
Reported frequencies derived from the Italian AIEOP AML 2002/01 protocol that enrolled 482 patients from 
2002 to 2012
3
. Modified from G. Basso Hematology Education 2014. 
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